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ABSTRACT

The fact that the proopiomelanocortin (POMC) gene is a critical component of
energy homeostasis and the stress response, two distinct yet not exclusively separate
biological functions, distinguishes this gene as very intriguing and unique for st lllldy.
The POMC gene encodes a preprohormone that is post-translationally processed
into multiple bioactive peptides. The tissue specific regulation and tissue specific
post-translational modifications provide a means for the broad spectrum of the
gene's biological activities. Understanding the POMC gene's cell-specific regulation
and the physiological functions of its encoded peptides has been an ongoing project
of multiple labs spanning the last two decades.

Initial studies predominately

revolved around the role of the POMC peptide adrenocorticotropin-stimulating
hormone's (ACTH) function as a key descending-component of the hypothalamicpituitary adrenal axis. Recently, the majority of studies have transitioned to a focus
on the hypothalamic POMC peptide, a.-MSH, and its anorexigenic effects. This
focus is with good reason. Within affluent societies, the rampant increase in obesity
and overweight prevalence and the associated risk for several chronic diseases has
accentuated the need for understanding the biological mechanisms of energy
homeostasis.

Using the murine rodent for its genetic advantages, this thesis

attempts to further advance our understanding of the POMC system regarding its
gene expression, neuron physiology, and biological functions.

xxii

Localization of the leptin receptor on POMC neurons together with the elevation in
POMC mRNA following intracerebroventricular (icv) injections of leptin or
neuropeptide Y (NPY) identified these hypothalamic neurons as a critical nodal
point in the central regulation of energy homeostasis. However, due to the limited
number of these neurons, POMC gene expression and regulation and the analyses of
synaptic events in response to peripheral or central signals has been limited. We
generated a transgenic C57BL/6 mouse line expressing enhanced green fluorescent
protein (EGFP) under the transcriptional control of POMC genomic regulatory
elements to facilitate the identification of these neurons in living brain slices and
primary cultures. The generation of the POMC/EGFP transgenic mouse has led to
the quantification of these hypothalamic neurons along with in vivo
electrophysiological characterization of the leptin response. Additional
electrophysiological studies using the POMC/EGFP mouse have provided a
mechanism for the effects of the anorexic drug, D-fenfluramine by indirectly
stimulating serotonin (5-hydroxytryptamine, 5-HT) receptors on POMC
hypothalamic neurons.

Most recently in vivo experiments with POMC/E GFP

neurons showed that they were stimulated by the gut derived PYY 3_36 hormone.
Studies have also revealed the POMC neurons to be glucose-responsive neurons that
express

KATP

inward-rectifying channels and the inhibitory neurotransmitter

_-amino butyric acid (GABA).

These studies described above have provided

essential insight regarding hypothalamic POMC neurophysiology.

XXUl

Whether the hypothalamic POMC peptides have functions that are exclusive to
hypothalamic neurons or whether pituitary POMC cells provide a redundancy for
these hypothalamic neurons was not known. Utilizing promoter-mapping data, we
generated a transgene that would selectively rescue pituitary POMC while retaining
the neuronal POMC deficiency when crossed onto a POMC null mutant that we
obtained fr om t he Hochgeschwender laboratory.

Our studies revealed that

replacing pituitary POMC (Pomc_1_; Tg/+) was not sufficient to rescue the
phenotypes caused by the ubiquitous absence of POMC peptides in the Pomc_,_ mice.
In fact some of the phenotypes present in the Pomc_,_ mouse, such as obesity and
diabetes, were accentuated in the mice lacking only CNS POMC. Obesity in the
Pomc_,_ mice resulted from a decrease in their basal metabolic rate (BMR).
Replacing pituitary POMC and thus glucocorticoids resulted in a further depression
in the mouse's BMR. Replacing pituitary POMC did not normalize the HPA axis
but instead further suggested a regulation of the HP A axis, independent of
glucocorticoids, by hypothalamic POMC neurons. The lack of CRH suppression in
the presence of elevated circulating corticosterone in the Pomc-1-; Tgl+ mice lead us
to the previous conclusion. CRH is a known anorexigenic peptide and evidence
supporting the opposing regulation of these neurons by POMC peptides, a-MSH
and P-endorphin, makes this hypothalamic circuitry very intriguing for not only
future stress axis studies but energy homeostasis studies as well.
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CHAPTER I

AN INTRODUCTION TO THE
PROOPIOMELANOCORTIN SYSTEM

Portions of this chapter have been published in:
Smart, J.L. and Low, M.J., (2001). "Spontaneous and Induced Genetic Mutations of the
POMC System;" Transgenic Models In Endocrinology. Editor Mario Castro, Kluwer
Academic Publishers, Boston!Dordrecht/London, pp 175-194.

1.

THE PROOPIOMELANOCORTIN GENE

1.1

Discovery and history of the POMC Gene

The discovery that one gene encoded more then one peptide was first realized in the
cloning of the proopiomelanocortin (POMC) gene.
(ACTH), beta-endorphin

(~-End)

Adrenocorticotropic hormone

and the melanotropins (MSHs) are all derived from a

single large precursor molecule, the POMC preprohormone, by individual processing
through a series of co- and post-translational modifications (Mains, Eipper et al. 1977).
The finding at the time that a single precursor encoded multiple yet distinct bioactive
peptides was novel. Although the phenomenon of an existing inert precursor molecule
was not realized until1977 the concept was first perceived a decade earlier, as a result of
analyses of structural forms and biological activities of beta-lipotropic hormone

(~-LBH)

[reviewed in (Chretien, Benjannet et al. 1979)]. The most surprising biological activity
was the morphine-like response to C-terminal fragments of
attributed to the endogenous opioid,

~-End.

~-LPH ,

which later was

When the POMC preprohormone was first

identified, the POMC peptides were known only to exist in the pituitary gland, but later
the discovery of the POMC preprohormone led scientists to hypothesize that all
neuropeptides were products of larger precursor molecules.

Later in vivo studies showed that POMC prohormone fragments lacked the classical
endocrine effects while behavioral influences of these peptides were noticed. The
various behavioral effects on motivation, attention, arousal, learning, memory, sleep,
drug-seeking behavior, development of tolerance and drug dependency led to the
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hypothesis that the central nervous system (CNS) must be a target of these hypophyseal
hormones (De Wied and Jolles 1982). However, explaining how pituitary-expressed
POMC peptides were able to reach targets within the CNS proved to be problematic. It
was thought that small peptides might be able to reach their targets by crossing the bloodbrain barrier via the bloodstream or by a retrograde transport from the pituitary gland.
These questions have yet to be completely resolved but an alternative explanation
surfaced from the finding that POMC peptides were also expressed in the CNS (Akil,
Watson et al. 1978; Watson, Akil et al. 1978; Watson, Richard et al. 1978). A subset of
neurons found in the arcuate nucleus (ArcN) was shown to express POMC mRNA and
peptides with their projections extending throughout the limbic system (Watson, Akil et
al. 1978; Gee, Chen et al. 1983). The finding of POMC peptides in the CNS, once
thought only to be expressed in the pituitary gland, led investigators to try and understand
the importance of pituitary derived POMC peptides versus hypothalamic derived POMC
peptides.

The task of unveiling and assigning individual roles to these peptides

expressed in the CNS versus the pituitary, which began two decades earlier, is still being
addressed today and is a major emphasis of this thesis.

1.2

Murine Pomc Gene Expression and Ontogeny

Po me is expressed most abundantly in corticotroph and melanotroph cells of the pituitary
but identical Pomc expression to that in the pituitary is also present in the brain (Orwoll,
Kendall et al. 1979; Palkovits, Mezey et al. 1987). POMC preprohormone and its derived
peptides are produced in neurons of the hypothalamic arcuate nucleus (ArcN) along with

3

the commissural nucleus of the solitary tract (NTS) in the brainstem (Berry and Haynes
1989). POMC neurons undergo final cell division at embryonic day twelve (e12)
preceding other neurons in the ArcN (Shimada and Nakamura 1973; Zachary, Woll et al.
1987; Rius, Barg et al. 1991). Expression of the POMC peptides in the ArcN coincides
with neurogenesis while other well-known hypothalamic peptides (vasopressin and
oxytocin) are not expressed until after neurogenesis (Shimada and Nakamura 1973). In
the spinal cord POMC mRNA and peptides, alpha-melanocyte stimulating hormone (aMSH) and B-endorphin

(~-End),

are transiently expressed (Rius, Barg et al. 1991 ). The

transient or early ontogeny of the POMC mRNA and peptides is indicative of a
developmental role in embryogenesis discussed later in this chapter.

Central POMC neurons project to nuclei within the forebrain, hypothalamus, thalamus,
mesencephalan and medulla. Some of the POMC neurons send projections that terminate
on the primary capillary bed of the hypothalamohypophyseal portal system much like
corticotrophin-releasing hormone (CRH) neurons originating in the hypothalamic
paraventricular nucleus (PVN). POMC peptides released onto the primary capillary bed
known as the median eminence can then be transported via the hypothalamohypophyseal
portal vasculature to the neurohypophysis also referred to as the posterior lobe of the
pituitary gland.

The early expression of hypothalamic POMC peptides, first detected at embryonic day
10.5 (e 10.5) shortly after neurogenesis, suggests a possible developmental role for this
peptidergic system (Elkabes, Loh et al. 1989). Interestingly, the interconnection between
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hypothalamic POMC and the pituitary gland could provide a neuro-anatomical
mechanism for stimulating undifferentiated pituitary cells into POMC expressing
corticotrophs and melanotrophs. These pituitary POMC expressing endocrine cells cannot
be immunocytochemically detected until embryonic days e12.5 and e14.5, respectively
two to four days after hypothalamic expression (Finley, Lindstrom et al. 1981 ; Palkovits,
Mezey et al. 1987; Elkabes, Loh et al. 1989).

Although the highest levels of POMC expression is in the pituitary and hypothalamus,
POMC expression can be detected at low levels in several tissues including the pancreas,
testis, kidney, liver, lung, duodenum, colon, stomach, lymphocytes, spleen and skin
(Smith and Funder 1988). My studies described within this thesis were confined and
focused to that of pituitary and hypothalamic POMC peptides, and to understanding their
separate and distinct physiological roles within these two tisssues. Further analyses are
needed to evaluate the roles of POMC peptides in the other tissues of POMC mutant
mice.

1.3

Processing of the POMC Prohormone

POMC mRNA is processed into two types of neuropeptides, the melanocortins (mainly
ACTH and a -MSH) and an opioid (f3-Endorphin). As mentioned previously, the
principal sites of POMC expression are corticotrophs and melanotrophs of the pituitary
gland and subsets of neurons in the arcuate nucleus (ArcN) of the hypothalamus and in
the caudal nucleus of the solitary tract (NTS) within the dorsal vagal complex of the
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medulla. This section will serve only to introduce major points relevant to the mouse
models discussed in this thesis.

For the most part, all the POMC peptides are processed from the prohormone by
enzymatic cleavage at basic amino acid residues. The majority of POMC prohormone
processing occurs in secretory vesicles with the exception of the N-terminal signal
peptide being cleaved by a peptidase in the endoplasmic reticulum (ER), the
glycosylation in the ER and Golgi apparatus, and the phosphorylation and sulfation also
in the Golgi apparatus (Eipper and Mains 1980; Hoshina, Hortin et al. 1982; Bennett,
Brubaker et al. 1983; Bourbonnais and Crine 1985). A variety of studies, most of which
where conducted in a corticotroph tumor cell line (AtT -20 cells), revealed how the
POMC prohormone is processed into its bioactive peptides (Eipper and Mains 1977;
Chretien, Benjannet et al. 1979; Eipper and Mains 1980; Policastro, Phillips et al. 1981;
Estivariz, Carino et al. 1988; Estivariz, Morano et al. 1988; Bicknell, Lomthaisong et al.
2001). Endoproteolytic cleavage of POMC by a prohormone convertase (PC1/PC3) in
corticotrophs yields ACTH, j3LPH, and an NH2-terminal peptide (Pro-A.MSH) (Figure 1).
The processing of these peptides from the prohormone is done by PC 1/PC3 recognizing a
dibasic residue: Lys/Arg.

The NH2-terminal peptide (Pro-A.MSH) and/or further

proteolytic derivatives have been postulated to mediate paracrine growth and secretory
effects within the anterior lobe and to stimulate mitogenesis in the adrenal cortex (Seger
and Bennett 1986; Denef and Van Bael 1998; Denef, Roudbaraki et al. 2001). A small
proportion of j3-LPH is cleaved to yield A.-LPH and 13-Endr-31· However, in melanotrophs
of the intermediate lobe virtually all 13-LPH is cleaved by PC2 to A.-LPH and 13-Endr-31·
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Figure 1
Processing of the POMC prohormone in anterior pituitary, intennediate pituitary,
and hypothalamic neurons.
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Unlike PC1/PC3, the PC2 endopeptidase activity is a result of PC2's recognition of all
dibasic residue combinations: Arg/Arg, Lys!Lys, Arg!Lys, and Lys/Arg.

Within the pituitary gland PC 1/PC3 is the primary processing enzyme in anterior lobe
corticotrophs while PC2 is the processing enzyme in intermediate lobe melanotrophs.
The ratio of PC1/PC2 present within POMC cells, which fluctuates more during
ontogeny, determines the processing of a-MSH and

~-Endr-3 1

(Marcinkiewicz, Day et al.

1993). The latter peptide is acetylated on its NH2-tyrosine and truncated by the action of
a carboxypeptidase to yield Ac-I3-End1-2? and Ac-13-Endr-26· Most of the acetylation is
thought to occur in the intermediate lobe of the pituitary gland (Glembotski 1982;
Glembotski 1982). Depending on the peptide being acetylated, this posttranslational
modification results in either a more or less active peptide (Guttmann and Boissonnas
1961; Smyth, Massey et al. 1979). The acetylated opioid peptides have a greatly reduced
affinity for 1-1 and c3 opioid receptors and their biological function has not been
satisfactorily determined. a-MSH is acetylated on its NH2-serine and amidated on its
COOH-terminal to yield a fully bioactive peptide.

~-MSH

is an additional

endoproteolytic product of human y-LPH but is not generated from rodent y-LPH because
it lacks the necessary consensus amino acid sequence for cleavage by a PC.

Endoproteolytic processing of POMC in ArcN neurons closely mirrors the processing in
intermediate lobe melanotrophs. a-MSH, ACTH, and 13-End are all processed in POMC
neurons. The neuronal a-MSH is fully amidated, but there is minimal NH2-acetylation
of peptides or COOH-terminal shortening of
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~-Endr-JI

in the CNS (Smith and Funder

1988; Castro and Morrison 1997; Pritchard, Turnbull et al. 2002). Additionally, A.-MSH
and/or A.-3-MSH are processed from the NH2-POMC domain in the ArcN.

A variety of peripheral tissues have been shown to express POMC mRNA, however it
has remained difficult to detect any significant amount of peptides (Smith and Funder
1988). One tissue in which POMC peptides have been detected is in the skin (Slominski,
Paus et al. 1992; Slominski, Ermak et al. 1995). The expression ofPOMC peptides in the
skin suggests possible paracrine and/or autocrine roles of these peptides. The POMC
peptide a-MSH and MCIR are known regulators of skin and hair pigmentation.

2.

POMC GENE REGULATION

2.1

POMC Promoter

A standard method to characterize the cis DNA elements and transcription factors that
control POMC gene transcription has been the expression of fusion genes, consisting of
POMC promoter sequences and a reporter sequence, in transfected cell lines. The most
commonly used cell line is AtT20, originally derived from a radiation-induced pituitary
tumor (Furth, Gadsen et al. 1953). These cells have many characteristics of primary
corticotrophs. Small cell lung cancers often ectopically express POMC and cell lines
derived from these tumors have also been used for the analysis of POMC gene expression
(Picon, Bertagna et al. 1999). It is clear, however, that neither of these cell lines are
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adequate models for elucidation of the mechanisms governing neural-specific expression
of the Pomc gene. For this reason, the Low laboratory has focused on a transgenic mouse
approach for the identification of cell-type specific regulatory elements in the POMC
gene.

The Drouin laboratory was the first to report the generation of transgenic mice expressing
a neomycin-resistance coding sequence (neo) from 770 bases of the rat POMC promoter
(Tremblay, Tretjakoff et al. 1988). Although the expression pattern in pituitary and
regulation by adrenalectomy and dexamethasone were consistent with accurate cellular
expression of the trans gene, the low levels of transcript from the neo reporter prevented
the direct demonstration of corticotroph and melanotroph specific transcription. The Low
laboratory initially approached this problem using an E. coli lacZ reporter gene encoding
B-galactosidase, which was useful for both the precise cellular identification of trans gene
expression and quantitation of transcriptional activity by an enzymatic assay utilizing a
fluorigenic substrate. These studies demonstrated that 770 bases of the rat POMC
promoter from nucleotide -706 in the 5' flanking sequences to +64 in the 5' untranslated
region of exon 1 were sufficient to direct lacZ expression selectively to pituitary
corticotrophs and melanotrophs (Figure 2, POMC-LacZ) (Hammer, Fairchild-Huntress et
al. 1990). The ontogeny of transgene expression also closely approximated the time
course of endogenous POMC gene expression in the two lobes of the pituitary gland.
However, there was no detectable expression of the -706POMC-lacZ transgene in the
brain suggesting that additional genomic sequences were necessary for. neuronal
transcription.
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Figure 2
Restriction maps of the mouse POMC gene locus, transgene constructs utilized to
map the location of tissue-specific regulatory elements, and targeted POMC
alleles that either selectively prevent B-endorphin production or result in the
absence of all POMC peptides.
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Additional studies from the Low laboratory analyzed the rat POMC promoter in more
detail to define the minimal elements essential for pituitary expression (Liu, Hammer et
al. 1992; Liu, Mortrud et al. 1995). Accurate cell specific colocalization was verified in
all instances by double-label immunofluorescence histochemistry. Truncations of the rat
POMC promoter to nucleotide -323 or -234 had minimal effects on both the ratio of
expression-positive to total transgenic pedigrees and qualitative levels of reporter
expression in the positively expressing lines.

Further deletion of the 5' flanking

sequences to nucleotide -160 abolished expression in the pituitary gland. Transfection
studies in AtT20 cells had identified important regulatory elements in the core promoter
region of the POMC gene.

However, the Low lab demonstrated that the enhancer-less

promoter and TATA box from the HSVl thymidine kinase gene were equivalent to the
native POMC promoter sequences between nucleotides -34 and +64, in the context of
upstream flanking sequences of POMC, to support pituitary cell specific expression and
normal up regulation by adrenalectomy. Based on these promoter truncation studies in
transgenics and additional data from DNAse I protection assays and gel shift assays
utilizing POMC oligonucleotide probes and fractionated nuclear proteins from AtT20
cells, the Low laboratory designed a series of more discrete mutations in the rat POMC
promoter. This second generation of transgenic experiments identified two functionally
important protein-binding sites at nucleotide positions -262/-253 and -202/-193 of the
POMC gene (Liu, Mortrud et al. 1995). At least one of these sites had to be intact to
support detectable pituitary expression of the transgenes. In addition, the ubiquitous
transcription factor SP1 appeared to play a supportive role in POMC transgene
expression through its interaction with DNA sites at positions -201/-192 and -146/-136.
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None of the transgene constructs that were studied selectively directed expression to only
pituitary melanotrophs or corticotrophs, suggesting that both cell types share one or more
essential components for POMC gene transcription. In common with most published
transgenic promoter analyses, the Low lab observed a large quantitative and qualitative
range of expression levels among independent pedigrees for each construct. It has been
suggested that these mosaic patterns of gene expression are influenced by repressive
effects of multiple-copy transgene integration in some cases (Garrick, Fiering et al.
1998). In general, basal expression of the trans genes appeared to be greater in individual
melanotrophs than corticotrophs, regardless of the type of reporter molecule.

The data from the Low laboratory transgenic promoter analyses revealed a number of
inconsistencies with the mapping of functional POMC promoter elements by transfection
studies in AtT20 cells. These differences may be due in part to the more stringent
requirement in transgenic mice for the definition of cell-specific expression and the
importance of chromatin remodeling during in vivo development. However, there is good
agreement between both kinds of studies for the key importance of DNA elements
between nucleotides -160 and - 323 in the 5' flanking domain of the POMC gene. This
region contains a site between -173/-160 that appears to mediate the transcriptional
activating effects of both CRH and the cytokine leukemia inhibitory factor (LIF),
although it is neither a binding site for CREB, AP-1 or STAT proteins (Bousquet, Ray et
al. 1997). In contrast, the POMC TATA box, a putative AP-I binding site in exon 1, and
more distal sites in the POMC 5' flanking sequences that bind helix-loop-helix (HLH)
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proteins and confer a synergistic activation of POMC expression in AtT20 cells do not
appear to be essential for pituitary cell-specific expression in the in vivo paradigm
(Therrien and Drouin 1993).

Recent data from the Drouin laboratory has identified yet another trans-acting factor,
Tpit. Tpit is a novel transcription factor belonging to the T-box gene family and its
discovery was a result of noticing the sequence similarities between a critical cis-acting
sequence in the Pomc promoter along with the consensus binding-site for T-box
(Lamolet, Pulichino et al. 2001). This transcription factor is exclusively expressed in
developing corticotrophs and melanotrophs and is capable of converting cells in the pars
tuberalis from thyrotropes to corticotropes. While differentiation of corticotrophs does
occur in the absence ofTpit, this transcription factor is essential for POMC expression in
mature cells. Deletion analyses of the Tpit gene in a designed mutant mouse has shown
that the lack of Tpit results in a diminished number of pituitary POMC cells with a
marked increase in gonadotrophs and thyrotrophs (Maira, Couture et al. 2003).
Additional data from Drouin's lab suggests an antagonistic interaction between Tpit and
the gonadotroph-restricted factor (SF1), and it may be this antagonism that regulates
which cells differentiate into POMC expressing corticotrophs and melanotrophs
(Pulichino, Vallette-Kasic et al. 2003). Mutations of the Tpit gene in both humans and
mice result in ACTH deficiencies (Pulichino, Vallette-Kasic et al. 2003).
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2.2

Hormonal Regulation of POMC

Leptin, an adipocyte secreted hormone, acts to stimulate POMC neurons while
synergistically inhibiting NPY neurons localized to the ArcN of the hypothalamus (Elias,
Aschkenasi et al. 1999; Cowley, Smart et al. 2001). Leptin and hypothalamic POMC
neurons are discussed in more detail in the following chapter.

Glucocorticoids are potent regulators of energy homeostasis and POMC expression both
in the hypothalamus and in the pituitary gland (Roberts, Budarf et al. 1979). During
fasting and when energy levels are in deficit, circulating levels of gJucocorticoids
(corticosterone in mice) increase which stimulates food consumption and energy storage.
Glucocorticoids modulate carbohydrate metabolism, converting stored proteins to
carbohydrates. Within the CNS, these regulatory effects are carried out by attenuation of
central anorexogenic and/or catabolic effectors like POMC, CART and CRH by
glucocorticoids (Schwartz, Woods et al. 2000). In the pituitary, glucocorticoids inhibit
anterior lobe POMC expression while in the intermediate lobe glucocorticoids seem to
upregulate POMC expression [reviewed in (Autelitano, Lundblad et al. 1989)].

In addition to leptin and corticosterone, gonadal steroids are known to influence food
intake and body weight. Estrogen behaves very similarly to that of leptin: decreasing
food intake and body weight and increasing metabolism. While estrogens are catabolic,
androgens tend to be anabolic: increasing food intake and body weight [reviewed in
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(Mystkowski and Schwartz 2000)]. Estrogens have been shown to be inhibitory to
POMC and CRH, yet testosterone is stimulatory to POMC (Wilcox and Roberts 1985;
Blum, Roberts et al. 1989; Tong, Zhao et al. 1990). While there are definite interactions
between gonadal steroids and energy homeostasis it is believed that these steroids play
more of a modulatory role rather then an essential role in maintaining energy
homeostasis. However, it may be these modulatory roles that are responsible for sexually
dimorphic phenotypes seen in some of our mutant mouse models.

3.

RECEPTORS OF POMC PEPTIDES

3.1

Melanocortin Receptors

Five distinct members of a G-protein coupled melanocortin receptor gene family have
been cloned (reviewed in (Cone, Lu et al. 1996)). MCI-R is expressed on melanocytes
within the skin and its activation by Ac-aMSH-NH2 leads to increased membrane
adenylyl cyclase activity by interaction with Gsa and subsequently greater production of
the brown-black eumelanin pigment and less of the yellow-red phaeomelanin (Table 1).
MC2-R is the classical ACTH receptor expressed on zona glomerulosa and fasiculata
cells of the adrenal cortex and it has very low affinity for the various melanocortin
peptides other than ACTH and ACTHI-24 (Mountjoy, Robbins et al. 1992).

Two

additional members of the gene family, MC3-R and MC4-R are expressed exclusively in
the CNS in partially overlapping but distinct neuro-anatomical areas with particularly
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Table 1

POMC Peptides and their Cognate G-Protein Coupled Receptors
Peptide

Cell of origin

Receptor

Target site

ACTH
Pro-yMSH

Corticotrophs
Corticotrophs

MC2-R
MC3-R,?

Adrenal cortex
Pituitary cells

Cort. secretion
Paracrine action

Ac-a.MSH-NH2

Melanotrophs

MC1-R

Melanocytes

Pigmentation

Ac-~-END 1-27

Melanotrophs

Peripheral sites

Modulation?

DesAc-a.MSH

Pituitary

Jl,a t Kd
MCSR

Secretion

yMSH,y 3 MSH

ARC neurons

MC3-R

Exocrine
glands
Limbic system

Homeostasis

DesAc-a.MSHNH2,ACTH

ARC neurons

MC4-R

Hypothalamus

Homeostasis

~-END1-31

ARC neurons

Jl = 6>x:

Diffuse CNS

Analgesia, reward

-

Function

Shown in the table are the POMC peptides relevant to this thesis matched up with their
known receptors and the target site of these peptides. Also listed is the POMC cell type
of the various peptides matched up with their known or believed physiological functions.
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high abundance in the hypothalamus and limbic system (Roselli-Rehfuss, Mountjoy et al.
1993; Mountjoy, Mortrud et al. 1994). The MC3-R has the highest affinity for A.-MSH,
although it is also activated by other melanocortins, while the MC4-R is activated most
selectively by a-MSH and ACTH. Together these receptor subtypes mediate most of the
described melanocortin effects on appetite, metabolism, thermoregulation, autonomic
outflow, and behavior.

The MC5-R is the most ubiquitously expressed of the

melanocortin receptors and its best documented function is the stimulation of exocrine
function including the sebaceous, preputial, Harderian, and lacrimal glands (Chen, Kelly
et al. 1997).

3.2

Mu-Opioid Receptor (MOR)

Three opioid receptor genes have been cloned corresponding to the !-'-, &, and

K

receptors

originally defined by their pharmacological profiles (Mansour, Watson et al. 1995 ;
Hayward and Low 1999). The

f-1.

opioid receptor is postulated to mediate much of

morphine-induced analgesia and physical dependence.

Classical pharmacological

experiments have shown that the various opioid receptor subtypes can mediate feeding
but these experiments are limited due to the unspecificity of the endogenous ligands for
the opioid receptors.

~-End 1 _ 31

has the highest and nearly equivalent affinity to both

[.!

and iS receptors (Pasternak 1993). However, each of these subtypes has significant
affinity for other opioid peptides derived from the proenkephalin and prodynorphin
precursors (Raynor, Kong et al. 1994). Two independent

f-1.

receptor deficient mouse

lines were generated in separate labs (Matthes, Maldonado et al. 1996; Sora, Takahashi et
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al. 1997). The!! receptor KO mice lacked morphine- induced analgesia seen in wild type
siblings confirming that the !! receptor is the receptor mediating morphine-induced
analgesia. No phenotypes exist in the !! receptor KO mice that suggest a disruption in
energy homeostasis.

4.

MUTATIONAL ANALYSIS OF POMC FUNCTION

4.1

Hypomorphic and Constitutively Active MCJ-R Gene Alleles

Classical genetic studies indicated that two independent loci, extension (E) and agouti
(A), primarily controlled the ratio of eumelanin and phaeomelanin in melanocytes, and

hence the color of individual hairs.

The extension locus is cell-autonomous and

approximately a decade ago was demonstrated to encode the MCl-R or MSH receptor
(Robbins, Nadeau et al. 1993). Numerous naturally occurring mutations at the extension
locus have been characterized genetically because of the relative ease in tracing the
mutant alleles during backcrosses and intercrosses by observation of coat color.
Recessive mutations of the mouse extension locus (e) result in a yellow coat color due to
low levels of tyrosinase activity in melanocytes and a high phaeomelanin/eumelanin
pigment ratio. Thee allele encodes a nonfunctional MCl-R resulting from a frame-shift
mutation and premature translational stop codon between the fourth and fifth
transmembrane domains. Dominant mutations of the mouse e locus result in black coat
color and are epistatic to agouti. The sombre (£50) allele encodes a MC1-R containing a
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single activating point mutation (Robbins, Nadeau et al. 1993).

This MCl-R is

constitutively active in the absence of MSH and therefore not antagonized by agouti
protein, accounting for the genetic epistasis (OHmann, Lamoreux et al. 1998). These
original data and the analyses of other mutant E alleles have been the basis of structurefunction models to explain receptor activation by agonist ligand binding. Interestingly,
identical mutations introduced into the other highly homologous MC-R subtypes have
generally not resulted in receptor activation, thus emphasizing the important functional
differences among these related G-protein coupled receptors and the danger of over
extrapolating data concerning ligand interactions from one receptor subtype to another.

4.2

Null Mutation of the MC4-R Gene

Targeted deletion of the MC4-R has shown it to play an important role in energy
homeostasis.

MC4-R is the predominant melanocortin receptor in the brain and

genetically engineered mice homozygous for a null MC4-R allele are obese, hyperphagic,
and exhibit increased longitudinal growth (Huszar, Lynch et al. 1997), all features shared
with the AY1ayellow mouse. These data and the inability of the potent non-selective MSH
analogue MTII to decrease food intake in MC4-R knockout mice (Marsh, Hollopeter et
al. 1999) indicate that the MC4-R is essential for the anorectic effects of central
melanocortins. Wild type mice given intraperitoneal administration of MTII exhibit
increased metabolic rates while MC4-R knockout (KO) mice given MTII have
unchanged metabolic rates suggesting that MC4-R may also regulate metabolism in
addition to feeding (Chen, Metzger et al. 2000). Additionally, the Palmiter lab has shown
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a metabolic defect in the MC4-R KO mice (Ste Marie, Miura et al. 2000). MC4-R KO
mice that were pair-fed with wild type siblings were shown to have an increase in body
weight, while non-pair-fed MC4-R KO mice show increases in body weight that precedes
their hyperphagia which suggests that the hyperphagia seen in the MC4-R KO mice may
be secondary to their metabolic defect. The anorexia and increase in metabolism seen in
acute and chronic illnesses, medically referred to as cachexia, is absent in MC4-R
deficient mice treated with lipopolysaccharide (LPS) or implanted with cachexigenic
sarcomas (Marks, Ling et al. 2001). Additional studies with the MC4-R deficient mice
revealed that increased thermogenesis in response to hyperphagia was lacking in these
mice, identifying the MC4-R as a critical component of diet-induced thermogenesis
(Butler, Marks et al. 2001 ).

4.3

Null Mutation of the MC5-R Gene

Transgenic mice deficient in the MC5-R do not exhibit any phenotypes that are directly
associated with weight regulation or feeding but they do exhibit thermoregulatory defects
and fail to repel water from their coat. These phenotypes were shown to be a result of
reduced production and secretion of lipids from sebaceous glands in MC5-R deficient
mice (Chen, Kelly et al. 1997). Additionally, the mice exhibited decreased production
and attenuated stress-induced synthesis of porphyrins by the Harderian glands and
decreased protein secretion from lacrimal glands. All of these exocrine glands, including
the preputial gland, are normally sites of high MC5-R expression. The results suggest the
existence of a hypothalamic-pituitary-exocrine axis that potentially regulates pheromone
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production from exocrine glands in coordination with the behavioral arousal state of the
mouse.

4.4

Null Mutations of the MC3-R Gene

Null mutations of the Po me (Yaswen, Diehl et al. 1999) and Mc4-r (Huszar, Lynch et al.
1997) genes, and transgenic over expression or mis-expression of the MC4-R antagonists
agouti and AGRP (Klebig, Wilkinson et al. 1995; Ollmann, Wilson et al. 1997) all
produce phenotypes that can be attributed to diminished MC4-R signaling. Although
these genetic models have provided great insight into the role of POMC and MC4-R in
energy homeostasis, little specific information can be extracted regarding a contributory
role of MC3-R signaling. The MC3-R, like the MC4-R, is expressed in the CNS but in a
more restricted distribution including ArcN and VMN. Two groups have independently
published reports of knockout mice lacking the MC3-R (Butler, Kesterson et al. 2000;
Chen, Marsh et al. 2000). MC3-R deficient mice exhibit nearly normal growth curves
and body weight, but carcass analyses reveal a significant increase in white adipose mass.
Additionally, MC3-R deficient mice are more susceptible than controls to developing
obesity on a high fat diet. In contrast to the obesity phenotype exhibited in MC4-R
deficient mice, which can mostly be explained by alterations in feeding behavior, the
MC3-R deficient mice apparently have a predominant metabolic defect involving energy
partitioning. They have higher feed efficiency and decreased lean mass. Mice lacking
both the MC3-R and MC4-R gain more weight than single MC4-R knockouts (Chen,
Marsh et al. 2000).

The MC3-R is localized presynaptically while the MC4-R is
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postsynaptically localized suggesting that the two receptors cannot compensate for the
lack of the other receptor. The fact that mice deficient in both genes have an additive
weight phenotype reveals that these two receptors are involved in two independent
pathways. Additional studies are needed to define the specific neural circuits responsible
for the divergent actions of melanocortin peptides, MC3-R, and MC4-R on the regulation
of food intake versus metabolic rate and energy expenditure.

4.5

Null Mutations of the Opioid Receptor Genes

Each of the three genes encoding the classical opioid receptor subtypes has been deleted
by homologous recombination in mice (Hayward and Low 1999). Surprisingly, there
have been no published reports regarding the effects of these mutations on food intake
and energy homeostasis. Based on our findings in the 13-endorphin-deficient mice, we
would predict that 1-l receptor knockout mice are the most likely to have a phenotype
relevant to the physiologic regulation of body weight and fat mass.

4.6

Null Mutation of the POMC Gene

The original POMC null mice on the mouse 129 genetic back ground are described later
in chapter 3 of this thesis.
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4. 7

fl-Endorphin-Deficient Mice

B-Endorphin-deficient mice were generated by the introduction of a point mutation into
the POMC gene by homologous recombination in embryonic stem cells (Rubinstein,
Japon et al. 1993). The nucleotide insertion at the amino-terminal tyrosine of B-End
introduced a premature translational stop-codon into exon 3 (Figure 1, construct
POMCX*4). Homozygous mice carrying this mutated allele express normal levels of
POMC mRNA in pituitary and ArcN. The mRNA encodes a COOH-truncated POMC
prohormone that is processed normally to ACTH and other melanocortin peptides
(Rubinstein, Mogil et al. 1996). The mice have no detectable immunoreactive B-End and
have been used to infer the normal physiological function of this specific endogenous
opioid peptide. Basal activity of the hypothalamic-pituitary-adrenal axis is normal and
the 13-End-deficient mice have normal corticosterone responses to a variety of stressors.
13-End-deficient mice exhibit unaltered nociceptive thresholds and unaltered antinociceptive responses to ip morphine administration. However, I3End-deficient mice fail
to exhibit endogenous opioid-mediated stress-induced anti-nociception and have
increased levels of non-opioid (naloxone insensitive) stress-induced anti-nociception
(Rubinstein, Mogil et al. 1996). Complimentary studies in enkephalin-deficient mice
have demonstrated that they retain endogenous opioid stress-induced anti-nociception
(Konig, Zimmer et al. 1996). Taken together, these data provide convincing genetic
evidence that B-End derived from the POMC prohormone, and not the more abundant
enkephalin peptides, is the natural opioid mediating stress-induced anti-nociception. The
most likely relevant neuro-anatomical substrate is the projection of ArcN POMC neurons
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to the central peri-aqueductal gray known to modulate descending anti-nociceptive
pathways to the brainstem and spinal cord.

More recent studies have demonstrated that the B-End-deficient mice have altered antinociceptive responses to morphine administered icv or it. The mutant mice are more
sensitive to the anti-nociceptive action of morphine injected centrally into the lateral
ventricle but less sensitive to morphine injected into the spinal compartment, compared to
wild-type control mice (Mogil, Grisel et al. 2000). The fl-specific agonist DAMGO
produced qualitatively identical results indicating the importance of the fl-Opioid receptor
in the phenotype. Total binding sites for the fl , 6, and

K

receptors, assessed by

quantitative autoradiography, were normal in the B-End-deficient mice suggesting that
subtle alterations in fl-receptor signaling may be the mechanism for the opposing
alterations in central and spinal sensitivity to morphine. An electrophysiological study
demonstrated a normal dose-response to DAMGO for the induction of an inwardly
rectifying K+ current (GIRK) in mediobasal hypothalamic neurons of the mutant mice
(Slugg, Hayward et al. 2000) consistent with the suggestion that fl-receptor number,
affinity, and coupling toG proteins are not altered by the complete absence of B-End.

Opioids, including f)-End, have generally been shown to increase food intake in
pharmacological studies (Morley 1987). Paradoxically, f)-endorphin-deficient mice
exhibit a sexually dimorphic obesity phenotype due to increased white fat mass in males
(Appleyard, Hayward et al. 2003). The male mice are slightly hyperphagic and have a
normal basal metabolic rate. This phenotype appears to be centrally mediated since
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rescue of B-endorphin expression to the pituitary alone does not reverse the phenotype
while re-expression in both the pituitary and hypothalamus does.

POMC derived

melanocortins and B-End are involved in a parallel, redundant anorexigenic pathway
within the hypothalamus but

~-End

additionally plays a role in an opioid reward pathway.

One hypothesis is the existence of a reward pathway that controls feeding behavior
mediated by

~-End.

Studies utilizing operant responding for food reinforcers, support

this latter hypothesis (Hayward, Pintar et al. 2002).

5.

POMC PEPTIDE FUNCTIONS

5.1

Hypothalamic Pituitary Adrenal Axis

The classic stress axis involves corticotropin-releasing hormone (CRH) that is secreted
from parvicellular neurons in the paraventricular nucleus (PVN). These parvicellular
neurosecretory cells terminate at the median eminence where they release CRH into the
primary plexus from which the peptide enters the hyophyseal portal veins. CRH then
acts on the corticotrophs in the anterior pituitary to release ACTH (Vale, Spiess et al.
1981). Finally, ACTH secreted into the systemic circulation reaches the adrenal gland
where it stimulates the production of corticosterone. POMC neurons are placed in a
manner lending to an important role in hypothalamic-pituitary-adrenal (HPA) axis
modulation. Although POMC involvement in this system is not fully understood, POMC
projections of the arcuate nucleus to the paraventricular (PVN) (Lu, Barsh et al. 2003),
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anteroventral periventricular (AVPv) nucleus as well as the previously described median
eminence provide an intriguing mechanism for modulating stress responses at nodal
central control points. Further anatomical evidence of POMC mediation of stress is that
POMC neurons impinge on the nucleus of the tractus solitarius: a brain stern nucleus.
Brain stern nuclei integrate autonomic system functions that are modulated during stress.
Interestingly, integral players in the stress response (glucocorticoids and CRH) stimulate
POMC rnRNA in arcuate nucleus consistent with regulatory feedback loops through
these hypothalamic neurons. Further, lesioning the arcuate nucleus in neonatal rats
blocks the characteristic stress-induced prolactin secretion (Johnston, Spinedi et al.
1984).

Abundant data implicate opioids as mediators of stress and reproductive systems. Sex
steroids administered exogenously and both female and male castration regulate POMC
rnRNA expression in hypothalamic neurons. These hypothalamic neurons project from
the arcuate to the medial pre-optic area (MPOA) of the hypothalamus. The stressinduced inhibition of the hypothalamic pituitary gonadal (HPG) axis may result from
direct or indirect inhibition of gonadotropin-releasing hormone (GnRH) neurons in the
MPOA via projections from POMC neurons in the arcuate nucleus. These and other data
support opiate involvement in modulating neuroendocrine systems in the hypothalamus.
Although mice deficient in B-End fail to support neuroendocrine modulation via B-End,
we have not been able to rule out any subtle compensatory mechanisms that may be
masking B-endorphin mediated actions.

29

5.2

Energy Homeostasis

Classical ablation or disconnection experiments utilizing electrolytic and chemically
generated lesions or knife cuts of the mammalian brain revealed a number of discrete
areas within the medial-basal hypothalamus to be nodal-points in the regulation of energy
homeostasis [reviewed in (Elmquist, Elias et al. 1999)]. One principal area characterized
in this fashion is the ArcN located at the base of the hypothalamus and adjacent to the
third ventricle. The ArcN extends rostro-caudally from the posterior border of the optic
chiasm to the anterior border of the mammillary nuclei. A subset of hypothalamic
neurons distributed throughout the ArcN express the POMC gene. These POMC neurons
densely innervate other brain areas implicated in energy homeostasis, motivated
behavior, and autonomic control including the dorsomedial nucleus of the hypothalamus
(DMH), paraventricular nucleus of the hypothalamus (PVN), lateral hypothalamic area
(LH), ventral tegmental area (VTA), parabrachial nucleus, and NTS.

The lesion studies showed that disruption of the mammalian ArcN correlated with an
obese phenotype and led to the concept that this area of the hypothalamus contained a
satiety center. Later efforts focused on determining the specific neuronal phenotype in
the ArcN that was involved in the regulation of energy homeostasis. An early indication
of the importance of POMC peptides was the detection of MSH binding by
autoradiography in the VMN, another hypothalamic nucleus involved in regulating
appetite and feeding (Tatro 1990). In addition, central or peripheral injections of
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melanocortin peptides were shown to affect food intake. Melanocortins appear to have
dual roles in energy balance, depending on the site of action. Administration of ACTH
and Ac-aMSH directly into adipose tissue increases lipolysis whereas intramuscular
injection of DesAc-aMSH increases food intake (Boston 1999). Furthermore, peripheral
DesAc-aMSH inhibits pituitary production of ACTH and Ac-aMSH, which may lead to
increased lipogenesis (Mountjoy and Wong 1997). MSH analogues administered icv or
injected stereotaxically directly into the PVN of rodents have potent anorexigenic effects
and stimulate metabolic rate (Farooqi, Yeo et al. 2000; Vergoni and Bertolini 2000;
Millington, Tung et al. 2001; Lim, Li et al. 2002). Exogenous opiates and endogenous
opioid peptides have also been shown to affect food consumption and food preference,
suggesting a role for POMC-derived

~-End,

in addition to the melanocortin peptides, as a

modulator of energy homeostasis (Reid 1985; Levine, Grace et al. 1994; Hope, Chapman
et al. 1997).

The physiology of this complex neuroendocrine system is virtually

impossible to replicate in in vitro models. Thus, transgenic mice and mice with naturally
occurring mutants or targeted genetic alterations have been extremely informative tools
for the analysis of POMC peptides and their receptors in the control of food intake,
energy partitioning, and body weight.

One of the first mutant mouse models of obesity to be studied was the lethal yellow
(Aria) mouse (Duhl, Stevens et al. 1994). The mutation arose spontaneously in the

C57BL/6 inbred strain and is associated with a striking yellow coat color and the
development of obesity and hyperphagia. Genetically, the mutation was shown to be
dominant to the extension (E) locus, later identified as the gene encoding the MC 1-
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receptor (Robbins, Nadeau et al. 1993). Cloning of the agouti gene revealed that it
encodes a secreted protein characterized by multiple pairs of intra-chain disulfide bonds
in its C-terminal domain. Agouti has high affinity binding for the MCI-R, antagonizes
receptor activation by MSH (Lu, Willard et al. 1994), and is normally transiently
expressed only in the hair follicles accounting for the yellow banding of individual black
hairs in the fur of many mammals. The mutant AY allele results from a 120 kb genomic
deletion and juxtaposition of the agouti coding sequences to the Raly gene locus and
subsequent ubiquitous expression of agouti protein from the Raly promoter (Duhl,
Stevens et al. 1994). These observations led to the agouti-obesity hypothesis, which
states that agouti protein expressed within the brain antagonizes the action of central
MSH to a neural MC receptor involved in regulation of energy balance. Some of the
experimental models reviewed in this chapter provide essential data in support of this
hypothesis, which has been further validated by the discovery and cloning of an agouti
homologue, agouti gene-related protein (AGRP). AGRP is expressed in the nervous
system and functions as an antagonist of central MC receptors (OHmann, Wilson et al.
1997).

Genetic linkage studies and quantitative trait loci analyses have strongly implicated the
POMC gene locus as an important determinant of weight homeostasis in humans of many

different ethnic populations, although specific alleles associated with obesity have not yet
been demonstrated (Comuzzie, Hixson et al. 1997; Hager, Dina et al. 1998; Hixson,
Almasy et al. 1999; O'Rahilly, Farooqi et al. 2003). Recently, mutations within the
coding region of the POMC gene that alter peptide activity have been identified (Krude,
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Biebermann et al. 1998; Krude and Gruters 2000; Challis, Pritchard et al. 2002; Krude,
Biebermann et al. 2003). However, a small number of children from cosanguineous
parents have been found to have null mutations in the POMC gene resulting in the
absence of detectable circulating ACTH (Krude, Biebermann et al. 1998; Krude and
Gruters 2000). These children presented with a syndrome of red hair, adrenal
insufficiency and severe, early-onset obesity. Alternatively, mutations in regulatory
regions of the gene may decrease the level of POMC expression in the brain although
such cases have yet to be found. In addition, both dominant and recessive mutations in
the MC4-R gene have been found in the human population, and MC4-R mutations have
been proposed to play a role in as many as 5% of pediatric obesity cases (Farooqi, Yeo et
al. 2000; Yeo, Farooqi et al. 2000).

5.3

Development

Both in vivo and in vitro, ACTH and aMSH have neurotrophic properties that benefit
neural growth during development and regeneration. Additionally, the robust early
expression (e10.5) of POMC in cell bodies and fiber tracts, at the same time as
hypothalamic neurogenesis, suggests a role for POMC peptides as trophic and/or
differentiating factors during ontogeny of the hypothalamus (Shimada and Nakamura
1973). Immuno-neutralization of POMC peptides leads to impaired brain development
during the late gestation period (Zagon and McLaughlin 1987).

Exogenous

administration of ACTH accelerates eye opening and motor behavior in up to 3-day-old
rats, while administration of ACTH after day 3 tends to prolong eye opening (De Wied

33

and Jolles 1982). Furthermore, administration of ACTH induces nerve sprouting in early
rat development (Frischer and Strand 1988).

Coinciding with the developmental

influence of melanocortins, opioids have also been shown to alter hypothalamic
development. An opioid antagonist given to rat pups resulted in increased dendritic
growth and dendritic spine formation in the brain (Hauser, McLaughlin et al. 1987).
Interrupting opioid-opioid receptor interactions by the immuno-neutralization of ~-End
during embryogenesis and neonates of rat pups up to 10 days old dramatically altered
neuro-ontogeny (Zag on and McLaughlin 1986; Zag on and McLaughlin 1987). Recently,
the developmental pattern of central melanocortin receptors 3 and 4 (MC3 -R & MC4-R)
revealed MC4-R to be the prominent receptor expressed during the entire fetal period
(Kistler-Heer, Lauber et al. 1998). Expression of MC4-R, shown by mRNA in situ
hybridization, occurred at a time when neural circuits are known to be forming, but the
mRNA message levels transiently peaked at these early embryonic time points. As
mentioned earlier, transient expression of spinal cord POMC mRNA and peptides, aMSH and 13-End, has also been reported (Elkabes, Loh et al. 1989). However, while the
transient or early ontogeny of the melanocortin receptor's mRNA and POMC peptides
are indicative of a developmental role in embryogenesis, it should be noted that studies of
the POMC null mice have yet to reveal any gross anatomical defects other than atrophic
adrenal glands.

Peripherally, the POMC derived peptide ACTH may also play a vital role in the
maturation of the neuromuscular junction (Cossu, Cusella-De Angelis et al. 1989).
ACTH appears to accelerate muscle strength, increase muscle contractility, and maintain
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motor units during nerve reinervation following nerve lesion (Sanes, Marshall et al. 1978;
Saint-Come, Acker et al. 1985; Berry and Haynes 1989). In vitro studies show ACTH as
a stimulator of adrenal cortical blastomere formation (Strand, Rose et al. 1991 ).
Maturation of peripheral organs such as the adrenal glands (Durand, Cathiard et al. 1984)
is thought to be induced by POMC but pituitary POMC is not detected until el2.5 in the
anterior lobe and e14.5 in the intermediate lobe. Adrenal blastomeres are present at ell,
suggesting that central POMC is providing maturational signals (Estivariz, Carino et al.
1988; Estivariz, Morano et al. 1988; Cossu, Cusella-De Angelis et al. 1989; Davis,
Burgess et al. 1989). While this thesis is not able to completely rule out a developmental
role of CNS POMC in adrenal maturation, we do show that pituitary POMC in the
absence of central POMC is sufficient for the development of ACTH-responsive adrenal
glands.

5.4

Pigmentation

In mammals, skin, coat and hair color are determined by the relative ratio of
phaeomelanin (yellow/red pigment) to eumelanin (brown/black pigment) produced by
melanocytes. In fur-bearing mammals, both MCl-R and agouti, an endogenous MC1-R
antagonist expressed in specialized cells in the dermis, affect this ratio. Activation of the
MCl-R by peripheral a-MSH stimulates eumelanin synthesis. Conversely, antagonism
of a-MSH action by agouti favors phaeomelanin synthesis (OHmann, Lamoreux et al.
1998). Expression of agouti is temporally and spatially regulated (Vrieling, Duhl et al.
1994). Temporal expression of agouti accounts for the agouti-banding pattern; spatial
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regulation accounts for differences in dorsal and ventral coat color seen in some
mammals. Additional reports hypothesize that agouti protein promotes melanocortinreceptor internalization, or that it functions as an inverse agonist of melanocortin
receptors (Siegrist, Willard et al. 1996; Siegrist, Drozdz et al. 1997).

Mutations ofMCl-R also have profound effects on pigmentation. Both gain-of-function
and loss-of-function mutations of MC1-R have been shown to alter pigmentation in a
range of species (Robbins, Nadeau et al. 1993). MCI-R is also highly polymorphic in
humans (Schaffer and Bolognia 2001 ). Certain allelic variants of the gene in humans are
associated with red hair and pale skin (Valverde, Healy et al. 1995). Although human
pigmentation is genetically complex, complete POMC loss-of-function mutations in
humans exhibited a deficiency syndrome that included red hair (Krude, Biebermann et al.
1998; Krude, Biebermann et al. 2003).

In humans, a-MSH and ACTH produced locally in the skin have a major role in
pigmentation [reviewed in (Thody 1999)].

The production of both peptides is

upregulated in the keratinocyte by ultra-violet (UV) radiation, and then act as paracrine
factors that stimulate the melanocyte to produce eumelanin. a-MSH is also produced by
the melanocyte and may act as an autocrine factor that affects eumelanin synthesis and
melanocyte morphology and as a paracrine factor that protects the melanocyte against
immune system damage. MC1-R has also been reported to be upregulated by UV
radiation. The contribution of centrally produced melanocortins on pigmentation has yet
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to be described, although the centrally produced forms of these peptides circulate at an
extremely low concentration.
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CHAPTER II

EXPRESSION OF ENHANCED GREEN FLUORESCENT
PROTEIN IN MURINE PROOPIMELANOCORTIN CELLS

Portions of this chapter have been published in or are in preparation for:
Cowley*, Smart*, et al. (2001) "Leptin activates anorexigenic POMC neurons through a
(*Co-First authors)
neural network in the arcuate nucleus." Nature 411, 480-484.
Overstreet, .. ... Smart, et al. (2004) "A transgenic marker for newly born granule cells in
dentate gyrus." Journal ofNeuroscience 23 (13): 3251-3259.
de Souza, .. . . .. Smart, ..... "Phylogenetic conservation of the modular enhancer
architecture that directs expression of the proopiomelanocortin gene to the hypothalamus
and brain stem of transgenic mice." In preparation for submission to Molecular &
Cellular Biology.
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1.

ABSTRACT

Proopiomelanocortin neurons in the arcuate nucleus of the hypothalamus and
nucleus tractus solitarius have prominent roles in the modulation of energy
homeostasis, autonomic function, and the stress response. However, the analysis of
signal transduction events and gene expression in these important peptidergic
neurons has been limited because there are only a few thousand POMC neurons in
the entire brain. To facilitate the identification of these neurons in living brain
slices or primary cultures, we generated a transgenic C57BL/6 mouse line
expressing enhanced-green-fluorescent protein (EGFP, Clonetech) under the
transcriptional control of POMC genomic regulatory elements.

Bright green

fluorescence was readily identified in the basal hypothalamus and in the NTS of the
brain stem: the two CNS regions where POMC is expressed.

Double-labeled

immunofluorescence with a B-endorphin antisera revealed >99% colocalization of
EGFP fluorescence and B-endorphin staining within the ArcN.

Pituitary

intermediate lobe (IL) melanotrophs and anterior lobe (AL) corticotrophs also
exhibited intense green fluorescence. The neuron-specific expression pattern of this
POMC-EGFP transgene further confirms the localization of critical genomic
regulatory elements in the 13kb of 5' flanking sequence of the POMC gene (Young,
Otero et al. 1998). Additional POMC-EGFP transgenic mice with truncated and/or
spliced 5' flanking sequences have subsequently been generated and have further
localized the regulatory elements essential for POMC neuronal expression.
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2.

INTRODUCTION

Abundant data from naturally occurring human mutations, engineered murine genomic
mutations, and pharmacological studies have identified POMC neurons as a critical CNS
component regulating feeding and metabolism. The ability to study these neurons in vivo
and unveil how the POMC gene is neuronally regulated has been complicated due to the
limited number of these cells. The discovery and cloning of the adipocyte hormone
Jeptin has led to significant advances in our understanding of how levels of peripheral
energy stores are regulated by the brain (Zhang, Proenca et al. 1994).

Leptin

administration to leptin-deficient humans, and the analogous oblob mice effectively
reduces hyperphagia and obesity (Campfield, Smith et al. 1995; Farooqi, Jebb et al.
1999). However, most human obesity is associated with elevated leptin, suggesting that
obese humans are less sensitive to leptin. In addition to its regulation of long term
physiological processes like energy balance and reproduction, leptin also exerts rapid
effects on neuronal activity (Haynes, Morgan et al. 1997; Haynes, Morgan et al. 1999;
Kim, Small et al. 2000). To understand the relationships between the acute and chronic
effects of leptin as well as the causes of leptin resistance it is necessary to precisely
characterize the cellular and neuronal mechanisms of leptin action.

Leptin's effects on energy homeostasis are mediated in part by leptin receptors expressed
on proopiomelanocortin (POMC) and neuropeptide Y (NPY) neurons in the arcuate
nucleus of the hypothalamus (ARC) (Hakansson, Brown et al. 1998; Cone 1999; Kalra,
Dube et al. 1999). NPY is a potent orexigen and decreases metabolic rate, while the
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POMC peptide a-MSH inhibits feeding and increases metabolic rate (reviewed in (Cone
1999)). Leptin may act on different neuronal subtypes in different ways. Acute leptin
treatment presumably activates POMC neurons, since increased immunoreactivity for the
immediate early gene c-fos in POMC neurons results from icv administration of leptin.
Conversely, leptin does not similarly activate NPY cells in the ARC (Elias, Aschkenasi et
al. 1999). Furthermore this second population of ARC neurons appears to be directly
inhibited by leptin (Glaum, Hara et al. 1996; Spanswick, Smith et al. 1997; Elias,
Aschkenasi et al. 1999). Understanding how peripheral signals like leptin are able to
relay information to the CNS is essential in understanding energy homeostasis.

The POMC gene is expressed in both endocrine cells of the pituitary gland and neurons
of the basal hypothalamus. POMC gene promoter mapping studies have identified the
DNA flanking regions essential for pituitary POMC expression (Liu, Hammer et al.
1992). In addition, the DNA flanking regions essential for neuronal POMC expression
were subsequently cloned from a cosmid mouse genomic library (Young, Otero et al.
1998). The DNA flanking regions obtained from these clones were 17 kb in size.
Although the DNA flanking cis elements for pituitary expression have been mapped to
-700 bp, the cis elements for neuronal expression have not been mapped as precisely.

The mapping of these essential POMC neuronal cis elements will eventually lead to a
better understanding of how this gene is regulated and consequently the discovery of
POMC gene transcriptional factors.

Understanding how the POMC gene with its

anorexigenic properties is regulated will help us unveil and understand putative key
factors in the balance between energy storage and utilization.
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3.

METHODS

Transgene construction. The transgene contains the entire transcriptional unit of the

mouse Pomc gene together with 13 kb of 5' flanking sequences and 2 kb of 3' flanking
sequences. An enhanced green fluorescent protein (EGFP) (Clontech, CA) cassette was
introduced into the 5' untranslated region of exon 2 within a mouse POMC genomic
clone. The EGFP cassette contains its own Kozac's consensus translation initiation site
along with SV40 polyadenylation site downstream of the EGFP gene directing proper
processing ofthe 3' end of the EGFP mRNA.

Creation of transgenic mice. The trans gene DNA was removed from its vector backbone

by Notl/Sall enzymatic digestion. Transgene DNA was purified by gel electrophoresis
followed by electro-elution from the agarose gel, phenol/chloroform extraction and
ethanol precipitation. DNA was then further purified and concentrated with an ELUTIPd kit (Schleicher & Schuell). DNA was quanitated by U.V. spectroscopy and an injection
concentration of 500 pmol of DNA in 5 mM Tris/ 0.1 mM EDTA/ pH 7.4 was used for
injections.

Pronuclear microinjections of linearized DNA into one-cell stage embryos of the inbred
C57BL/6J (Jackson Laboratories, ME) mouse strain were performed (Brinster and
Palmiter 1984). One founder was generated and bred to wild type C57BL/6J to produce
F I hemizygotic mice. In addition, F2 progeny and subsequent generations of mice
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homozygous for the transgene were also generated. The F2 mice were used to establish
and maintain a breeding colony. All founder mice were initially screened by genomic
DNA dot blots. After a mouse line was established, subsequent generations were
screened using PCR. Standard PCR genotyping was conducted on DNA extracted and
prepared from tail clippings.

PCR genotyping of pups was conducted on DNA extracted and prepared from tail
clippings (described in (Barnes 1994)). Touchdown PCR was used to favor amplification
of desired amplicons and to limit artifactual amplicons and primer-dimers (protocol
de sri bed in (Don, Cox et al. 1991) ). Multiple cycles were programmed so that the
annealing segments in sequential cycles are run at incremental lower temperatures
starting at the suspected melting temperature (Tm). To avoid low-Tm priming during the
earlier cycles it was imperative to apply a hot start modification to the PCR protocol
(D'Aquila, Bechtel et al. 1991). The programmed PCR cycle was 94°C for lOmin; [94°C30sec; 64°C minus 1OC per cycle-30 sec; 72°C-30 sec] X 15 cycles; [94°C-30sec; 50°C30 sec; 72°C-30 sec] X 15 cycles; 72°C-3min; hold at 4°C. The following primers were
used and were identified as EGFP-3 (5'-GAACTCCAGCAGGACCATGT-3') Tm=60°C
and EGFP-5 (5'-AGAAGAACGGCATCAAGGTG-3') Tm=58 °C which gave a PCR
product of 199 bp. A standard PCR reaction mix was used as described in the manual
"PCR Primer" (Dieffenbach and Dveksler 1995).

Southern blot. One centimeter of tail was removed for DNA extraction from mice that

were anesthetized with 2,2,2-tribromoethanol (0.15 mls/30g of a 2% w/v solution). The
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tails were placed into 0.5 ml of a (0.5mg/m1] proteinase K digestion buffer at 55°C
overnight on a rotating 'nutator'. The next day the mouse hair was centrifuged out of the
digestion buffer and 0.45 ml of isopropanol was added to the buffer to precipitate the
DNA. Salts were washed out of the DNA with 70% EtOH, allowed to air-dry and then
dissolved in a neutral pH Tris buffer. The DNA was then put through a
phenol/chloroform extraction to remove any proteins or debris that would hinder a
genomic DNA enzymatic digest and then salt precipitated with 10% sodium acetate and
2X volume ethanol. DNA was quantitated using U.V. spectroscopy so that equal
amounts of DNA (20

~g)

per mouse would be digest and loaded per well. Genomic

DNA was digested overnight with BamHI because only one BamHI site exist in the pHal
Ex2* transgene. With multiple insertion transgenes, they most commonly insert into the
mouse's genomic DNA at one locus in a head to tail orientation. A genomic DNA digest
using a restriction site that cuts once in the transgene will give a DNA band the size of
the transgene. DNA was loaded and run overnight at 30 mV on a 0.6% w/v low melting
point agarose gel made and run in 0.5X Tris-buffered saline. Gel was denatured,
neutralized and transferred onto nylon membrane following a standard Southern blot
protocol (Southern 1975). We used a random-primed POMC exon 3

eP]-DNA probe
2

made from a linearized 700 bp DNA segment. Using one probe that recognized both the
endogenous gene and the transgene allowed us to do a ratio analysis on the band
intensities. Averaging this ratio from 40 Southern blot lanes (each lane representing one
hemizygous POMC/EGFP mouse) gave us a trans gene copy number of 18 per
hemizygous mouse.
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Immunohistochemistry. Adult POMC/EGFP transgenic mice were anesthetized with 0.5

ml of 2% w/v 2,2,2-tribromoethanol (Avertin, Alrich, MO) and perfused transcardially
with 4% paraformaldehyde borate buffer pH 9.5. Coronal sections were cut on a
vibratome at a thickness of either 30

~-tm

or 50

~-tm

into 0.02M potassium phosphate

buffered saline pH=7.4 (KPBS). Free-floating sections were blocked for 24 hat 4°C in
KPBS containing 0.4% Triton X-100 and 2% normal horse serum (Vector Laboratories,
Burlingame, CA) with gentle agitation. Sections were then incubated for 24 h at 4 oc in
KPBS containing 0.4% Triton X-100 and 2% normal horse serum and primary antibody
of 1:2500 v/v rabbit anti-j3-endorphin (a gift from Dr. Oline Ronnekleiv original source
Dr. M.R. Brown) or 1:25000 v/v rabbit anti-NPY (Alanex Corp.) or 1:2000 v/v rabbit
anti-ACTH (a gift from Dr. Richard Allen) or 1:1000 v/v mouse monoclonal anti-TH
(Incstar) with gentle agitation. Sections were again rinsed in KPBS and incubated for 2-4
hat RT in KPBS containing 0.4% Triton X-100 and 2% normal horse serum and

10~--tgl~--tl

biotinylated horse anti-mouse/rabbit serum (1 :200; Vector Laboratories, CA) with gentle
agitation. Sections were again rinsed with KPBS and incubated for 1 hat RT in KPBS
containing 0.4% Triton X-100 and 1:500 v/v Cy-3 conjugated streptavidin (Jackson
Immunoresearch Laboratories, Inc. West Grove, PA) with gentle agitation. Sections
were then rinsed in KPBS for 3 h to reduce background. After rinsing, sections were
mounted and then air-dried onto gelatin-coated slides in a rostral to caudal orientation.
Slides were then placed in a 4

~-tgl~-tl

bis-benzimide solution (Sigma) for 5 min at RT to

stain cell nuclei. Slides were then rinsed and air-dried before cover slipping with
'vectashield' mounting media (Vector Laboratories, CA).
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Cell counting and co-localization. After tissue sections were processed for anti-13-

endorphin immunohistochemistry, sections were mounted on slides, air-dried and cover
slipped with 'vectashield' mounting media to prevent photo bleaching. These sections
(30!-tm) were mounted in a caudo-rostral orientation to assure accurate mapping of the

POMC neurons. Sections were viewed under a 20X objective for EGFP fluorescence
(green) and immunohistochemistry staining (red).

Care and use of animals. All animals for these studies were maintained under controlled

temperature and photoperiod conditions (14 h of light, 10 h of dark; lights on, 0500 h)
with food and water ad libitum. Maintenance of all animals and all surgical procedures
used were approved by the Institutional Animal Care and use Committee and were in
keeping with guidelines established by the National Institutes of Health (NIH).

4.

RESULTS

4.1

Generation and characterization of the initial POMCIEGFP (-131+8
POMCIEGFP) transgenic mouse line

In order to study in vivo physiological responses to peripheral signals like leptin, we
constructed reporter genes to be introduced into the murine genome via standard
transgenic technology. Utilizing a "Clontech Inc, CA." cassette containing the sequence
for enhanced green fluorescent protein (EGFP), we constructed a variety ofPOMC/EGFP
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transgenes. These transgenes were designed using POMC neuronal enhancer/promoter
sequences to inertly mark POMC expressing cells while also mapping the gene's
promoter regions essential for neuronal expression. The first POMC/EGFP transgene (13/+8 POMC/EGFP) that was constructed contained genomic sequences located between
-13kb and +2kb of the POMC gene (Figure 1).

In order to eliminate epistatic

modifications to phenotypes caused by genetic heterogeneity found among inbred mouse
lines, we used C57BL/6 mouse oocytes for pronuclear injections. The C57BL/6 inbred
mouse is commonly used as a background strain for many mutant mouse lines, and is
commonly used in mouse behavioral studies. Many of the mutant mouse lines of the
POMC system have been studied on this genetic background; furthermore, the C57BL/6
inbred mouse strain is susceptible to diet induced obesity lending this strain advantageous
for studying a type of obesity that is prevalent among human populations.

Pronuclear injections resulted in the generation of one male founder. This founder
mouse, as well as subsequent POMC/EGFP founder mice, was identified by a genomic
DNA dot blot. A radionucleotide 32P-labeled random-primed DNA probe was generated
from EGFP specific sequences and used to hybridize with tail DNA on the dot blot. The
male founder was then bred to C57BL/6 females to generate F1 progeny for transgene
analysis. Genotyping of F 1 progeny was done utilizing PCR techniques with EGFP
sequence-specific primers (see methods). A quantitative-Southern-blot, described in
greater detail in the methods, of mouse tail DNA using a ratio analysis of the endogenous
POMC gene and the transgene revealed the transgene copy number to be 18 copies per
hemizygous mouse (Figure 2).
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Figure 1

The POMC/EGFP transgene was constructed by subcloning the coding sequence
for enhanced green fluorescent protein and a polyA adenylation sequence from
bGH into an untranslated region of exon 2 of a mouse POMC genomic clone.
The POMC/EGFP transgene injected into mouse oocytes was -21 kb in length.
Both the transcriptional start and stop site are marked on the wild type allele (top)
and the POMC/EGFP transgene construct (bottom) depicted in this schematic.
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Figure 2

Using a radionucleotide labeled DNA probe generated from exon 3 ofthe POMC
gene, we could detect the endogenous alleles and the inserted POMC/EGFP
transgene by a quantitative genomic-Southern-blot. A densitometric ratio was
obtained from 40 lanes with each lane containing restriction enzyme (BamHI)
digested genomic tail DNA. Each lane represents one hemizygous POMC/EGFP
transgenic mouse and a ratio between the two bands revealed the transgene copy
number to be 18 copies. 10.5 kb, wild type allele; 11.5 kb, transgenic allele.
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Figure 2

EGFP Genomic Southern Blot
- - 11.5Kb
- - 10.5Kb

Using positive Fl progeny, initial immunohistochemistry studies revealed that the
expression of EGFP in hypothalamic neurons mirrored the expression of the POMC
peptide,

~-endorphin

(Figure 3). Under ultraviolet (450-480 nm) excitation, bright green

fluorescence (509 nm) was seen in the two CNS regions where POMC is expressed: the
ArcN and the NTS (Figure 4 ). Coronal sections of e 14.5 mouse embryos revealed
fluorescent cells in the basal hypothalamus along with the anterior and intermediate lobes
of the pituitary gland (Figure 5). Expression of EGFP in these three cell types at an
embryonic developmental stage when POMC has also been reported suggests the
trans gene is regulated similarly to that of the endogenous POMC gene (Elkabes, Loh et
al. 1989).

4.2

EGFP expression confined to hypothalamic POMC neurons is used to
count and map these neurons in the mouse

EGFP excitation in POMC neurons was clearly distinguished from adjacent, nonfluorescent neurons visualized under infrared optics (not shown) for a short period of
time to avoid damaging the cells/neurons and their circuitry.

But before

electrophysiological studies could be conducted on these fluorescent neurons, we needed
to assure ourselves that the fluorescence was confined to only hypothalamic POMC
neurons. Standard immunohistochemistry protocols, with traditional diaminobenzidine
(DAB) peroxidase reactions, are very harsh on cellular proteins and greatly diminish the
fluorescence of existing fluorophores. In order to circumvent this problem, we utilized a
rabbit polyclonal

~-endorphin

antiserum, a secondary biotinylated goat anti-rabbit IgG,
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Figure 3

Immunohistochemistry forB-endorphin is shown in panel (A) and for EGFP in
panel (B) on coronal sections of mouse hypothalami. Both immunohistochemical
analyses were done with primary rabbit polyclonal antisera for either B-endorphin
(panel (A)) or EGFP (panel (B)) followed with a biotinylated secondary antibody
and peroxidase DAB redox reaction.
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Figure 3
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Figure 4

Analysis of adult coronal brain sections also revealed strong EGFP expression in
both the ArcN and NTS. 50

~-tm

coronal sections visualized by ultraviolet

excitation (450-480 nm) revealed bright green fluorescent neurons in the basal
hypothalamus and caudal brain stem: the two CNS regions where POMC is
expressed. EGFP fluorescence can also be seen in processes extending two to
three cell body lengths from fluorescent soma. SolM= Medial Solitary Tract;
CC= Central Canal; 3V= Third Ventricle.
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Figure 4
A)

ArcN
B)

NTS

Figure 5

Basal Hypothalmus and Pituitary Gland
Embryonic Day (e14.5)

and then a tertiary strepavidin-Cy3 conjugate as the fluorophore: thus allowing the use of
dual fluorophores, EGFP & Cy3, within the same cell.

This immunofluorescence

analysis revealed >99% colocalization of EGFP and POMC peptides within the ArcN
with only six neurons lacking evidence of co-expression (n=l mouse) (Figure 6).
Additional immunofluorescent studies revealed close apposition of both tyrosine
hydroxylase (TH) and NPY stained terminals on EGFP expressing POMC neurons, and
no evidence of co-localization of the THor NPY immunoreactivity with EGFP.

Total fluorescent cell counts were performed on coronal hypothalamic sections of three
POMC/EGFP mice. The average number of POMC neurons from the three mouse
hypothalami was 3148 ± 62 (mean± s.e.m.; n=3). The POMC neurons from one mouse
hypothalamus were plotted on line drawings obtained from "The Mouse Brain in
Stereotaxic Coordinates" (Franklin and Paxinos 1997).

The POMC neurons are

distributed through the entire ArcN; interestingly, these POMC neurons in the mouse
tend to be found both medially and ventrally within the ArcN, in contrast to the rat where
they are mostly found in the lateral ArcN and the NPY neurons are found in the medial
arcuate nucleus (Figure 7).

4.3

Ectopic expression of EGFP in the CNS

While EGFP expression in the hypothalamus was confined to POMC neurons, ectopic
expression of EGFP was detected in a number of cell populations outside of the
hypothalamus. Green fluorescent cells were first noticed in the hippocampus in a discrete
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Figure 6

A) EGFP expression was visualized by ultraviolet excitation at 450-480 nm and
B) in the same section immunofluorescence for

~-endorphin

antisera (530-560

nm) shows transgene expression exclusively in arcuate nucleus POMC neurons.
C) Superimposed images revealed >99% co-localization of EGFP and

~

endorphin within the ArcN. Less then 1% of EGFP fluorescent neurons did not
contain

~-endorphin

staining, thus demonstrating a lack of ectopic expression

within the hypothalamus. D) Immunohistochemistry for tyrosine hydroxylase
(TH) shows that the hypothalamic dopaminergic neurons do not co-localize with
the EGFP fluorescent POMC neurons.
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Figure 6
B)

A)

EGFP

C)

Co-localization
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D)
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Figure 7
The bright fluorescence of neurons in the POMC/EGFP transgenic mice allowed
for easy mapping and counting of hypothalamic neurons. Hypothalamic coronal
sections (30f!m) were mounted on gelatin-coated slides from three male
hemizygous transgenic mice. Each section from all three mice was counted for
fluorescent cell bodies as well as anatomical mapping of these neurons within the
hypothalamus.

POMC/EGFP neurons are distributed throughout the entire

arcuate nucleus.
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group of cells in the dentate gyrus sending projections that extend partially up into the
molecular layer (Figure 8). The use of a polyclonal anti-EGFP antibody increased the
sensitivity for EGFP detection in the axons projecting to the stratum lucidum of CA3 and
short dentrites extending to the inner molecular layer (data not shown). EGFP was not
observed in the more superficial granule layers of the dentate gyrus or in any other region
of the hippocampus. Initially these cells were thought to be basket cells due to the
number, location, and distribution of these fluorescent cells. However, subsequent data
from a collaborating lab has identified these cells as a population of newly born granule
cells by both morphological and electrophysiological analyses along with using
bromodeoxyuridine (BrdU) labeling, a thymidine analog (data not shown). Cells that
incorporate BrdU during S phase were detected using anti-BruD-specific antibodies
following membrane permeablilization (Gratzner 1982). Co-localization of the BrdU and
EGFP confirmed that the fluorescent cells were not post-mitotic. As these transgenic
mice age, the number of EGFP fluorescent cells diminish and eventually in older mice
(sometime after 12 months of age) fluorescent cells in the hippocampus are markedly
diminished in number. At the same time in these older mice, hypothalamic POMC
neurons still express the EGFP protein. The BrdU labeling also showed that these newly
born granule cells migrate out of the dentate gyrus presumably as or after they
differentiate. After the cells migrate out of the dentate gyrus they no longer express the
EGFP protein suggesting that in the flourescent stem cells permissive factors/conditions
exist that allow for transgene expression. Subsequent transgenes carrying various
segments of 5' DNA flanking regions have identified a small region of DNA that is
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Figure 8
Ectopic expression was detected in a discrete population of cells in the
hippocampus. Fluorescent cell bodies can be seen in the inner granule cell layer
of the dentate gyrus using a FITC filter to detect EGFP green fluorescence. Total
cell nuclei are visualized by the DNA-binding fluorescent dye Hoechst 33258. A
higher power detail of the tip of the dentate gyrus is also shown.
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Figure 8

Hippocampus

required for the reporter genes to express in the hippocampal granule cells (see section
4.4). No evidence of endogenous POMC mRNA or POMC peptides expressed in this
brain region has been verified. In light of these findings, a closer developmental analysis
of POMC expression in the CNS may be warranted. Currently, our hypothesis is that
DNA silencing elements have been excluded in the construction of the transgenes due to
their distance from the promoter sequences used in our reporter gene constructs, thereby
allowing hippocampal expression. Recent data, in which transgenic mice have been
generated using bacterial artificial chromosome (BAC) vectors containing reporter
cassettes, has identified a BAC containing the Pomc gene that expresses in the
hippocampus (Gong, Zheng et al. 2003). In contrast to the arcuate nucleus, we were
unable to detect POMC immunoreactivity in the dentate gyrus using the polyclonal
antibodies (as previously described) raised against different POMC-derived peptides,
even in colchicines-treated mice (data not shown). In situ hybridization performed with a
mouse exon 3 riboprobe (described in chaper V) failed to detect POMC mRNA in the
dentate gyrus from early postnatal, 3 week-old, and adult transgenic and non-transgenic
m1ce.

Ectopic expression of EGFP was also visualized in the retina of a mouse embryo at age
e14.5 (Figure 9). Bright fluorescence could be detected extending from the retina
through the optic nerve to the optic chiasm. Retinal ganglion cells are the only cells
whose processes make up the optic nerve and so it is these cells that are most likely
expressing EGFP. Attempts to visualize EGFP fluorescence in adult mouse retinas has
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Figure 9

Ectopic expression could also be seen in retinal ganglion cells in e 14.5 mouse
embryos.

Bright green fluorescence was detected in the optic chiasm that

contains only retinal ganglion processes.
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Figure 9
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been unsuccessful. Further studies would be needed to determine if this expression is
transient and/or if the expression in these cells is similar to those in the hippocampus.

4.4

Mutational analysis ofthe Pomc 5' flanking region

Following the generation of the first POMC/EGFP transgenic mouse line
(~3'POMC27*/EGFP)

described earlier in this chapter, three additional transgenic lines

have subsequently been generated (Figure 10). Transgenic mice produced with - 10.5 to
8.0 POMC/EGFP showed identical netironal expression to the

~3'

POMC27*/EGFP

transgenic mice, while - 9.0 to 8.0 POMC/EGFP did not express in the CNS but pituitary
expression was present in these mice. These data have mapped essential neuronal cis
regulatory elements to a 1.5 kb region between -10.5 to -9.0 of the 5' flanking sequence
of the Pomc gene. All the above described transgenes, including the pHal* transgene that
has shown to express POMC peptides only in the pituitary (Rubinstein, Mortrud et al.
1993), show either EGFP or mRNA expression (pHal*) in the hippocampus. Conversely,
the

~

Sma POMC/EGFP transgenic mice, containing the same sequences as the

~3 'POMC27*/EGFP

mice minus 6 kb of sequence between the Smal sites, does not

express in the hippocampus but does express in the hypothalamus, brain stem and
pituitary. These data map a hippocampal regulatory element to - 2 to -0.8 kb of sequence
between the first EcoRI site and the second Smal site just a couple kb 5' to the POMC
promoter region (Figure 10).
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Figure 10

Wild type allele is shown at the top followed by transgene constructs with
variable lengths of DNA flanking regions of the Pomc gene.

~3'

P27* was first

shown to express in the CNS followed by ~3' POMC27*/EGFP which is identical
except for the EGFP cassette in exon 2. pHal* and - 9.0 to 8.0 constructs only
express in the pituitary while -10.5 to 8.0 POMC/EGFP construct expresses in the
pituitary and the CNS. Identifying a region -10.5 to -9.0 as containing neuronal
cis elements. POMC-LacZ reporter gene confirmed pituitary expressing cis

elements to be contained in -706 bp of 5' t1anking sequence.

~ Sm a

POMC/EGFP was the only transgene that expressed in the both CNS and pituitary
POMC cells but did not express EGFP in the hippocampal dentate, thus localizing
sequence directing dentate expression to a region that is -2 to - 0.8 from the
POMC promoter region.
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5.

DISCUSSION

A caveat of pronuclear DNA injections into mouse oocytes, with endogenous or novel
genes, is that the location and copy number of the transgene being inserted is
unpredictable and can sometimes result in adverse side effects such as disrupting an
existing gene (Brinster and Palmiter 1984; Palmiter and Brinster 1985). However, no
obvious behavioral phenotypes have been noticed in the POMC/EGFP mouse. The
Rubinstein lab used quantitative rt-PCR to measure Pomc and EGFP mRNA after leptin
administration. Unpublished results have shown that both Pomc and EGFP mRNA
levels increase in parallel after leptin injections. These data suggest the POMC/EGFP
transgene is regulated in a similar fashion as the Pomc endogenous gene. Such analyses
will be useful for studying the regulation of the POMC gene in the presence or absence of
promoter and/or putative neuronal transcriptional/regulatory elements. Consequently,
fluorescent protein tagged cells can be mechanically sorted to create an enriched POMC
cell population that can be easily identified for such in vitro studies and further in vitro
manipulations.

The ease of identifying fluorescent cells in fixed tissue provided an unambiguous method
for promoter analyses in transgenic founder lines. Using transgenes containing specific
deletions of 5' DNA flanking sequences, we have been able to narrow the region
containing the essential cis regulating elements for neuronal POMC expression to 1.5 kb
of 5' flanking sequence. In addition, ectopic hippocampal expression from a variety
reporter transgenes has identified cryptic sequences localized between -2 and -0.8 kb of
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the 5' flanking region upstream of the POMC promoter. Our failure to detect POMC
immunoreactivity or POMC mRNA in the mouse hippocampus was consistent with all
known POMC gene brain expression studies and therefore indicates that the hippocampal
EGFP expression was ectopic. Furthermore, the fact that independent pedigrees carrying
EGFP, as well as other reporter genes (Rubinstein, Mortrud et al. 1993), exhibited
hippocampal expression revealed that expression was not due to chromosomal influences.
Interestingly, this necessary region for dentate expression of reporter genes was
dispensable for appropriate expression oftransgenes in POMC cells ofthe hypothalamus,
the brain stem, and the pituitary.

In vivo identification of this sparsely populated group of POMC neurons led to

physiological experiments that previously were technically very difficult. With the help
of our collaborators in the Cone lab, electrophysiological observations allowed us to
propose a model of the dual mechanisms of leptin action in the ArcN and the interactions
between NPY/GABA and POMC neurons (Cowley, Smart et al. 2001). In this model
leptin directly depolarizes the POMC neurons, and simultaneously hyperpolarizes the
NPY/GABA neurons, probably at their presynaptic terminals. This hyperpolarization
diminishes GABA release and thereby disinhibits the POMC neurons. Together the
direct and indirect effects of leptin result in an activation of POMC neurons and an
increased frequency of action potentials. Additionally, both POMC and NPY neurons
express autoreceptors for some of their respective neuropeptide products and activation
of these autoreceptors may provide an ultra short feedback loops that further modulate
the effects of leptin on POMC neurons. Thus it appears that there are two classes of
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neurons accounting for leptin sensitivity m the brain, those that are activated
(depolarized) to release anorexigenic peptides, and those that are inhibited
(hyperpolarized) by signals that indicate energy repletion. Identifying POMC neurons
with EGFP provides an invaluable new tool for determining complex actions on these
important neurons. Furthermore, an understanding of the acute effects of leptin provides
new targets to test for defects in central leptin action, an important component of leptin
resistance.
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1.

ABSTRACT

Mice deficient in proopiomelanocortin peptides (Pomc- 1) generated on a 129
(Aw/Aw) genetic background were backcrossed onto the C57BL/6 (a/a) genetic

background. These mice exhibit most of the phenotypic characteristics previously
reported on the 129 genetic background (Yaswen, Diehl et al. 1999). Adult mice
became obese, their adrenals were atrophied, and they had undetectable plasma
corticosterone in basal and stressed states. The partial perinatal lethality previously
reported was also present on the C57BL/6 background. In addition, we found that
both male and female homozygote (-/-) adults are fertile, but when homozygous
males were intercrossed with homozygous females, all the pups died in the perinatal
period. Attempts to rescue the perinatal lethality of pups from homozygous breeder
pairs by supplementing the mother's drinking water with glucocorticoids were
unsuccessful.

Furthermore, failure to stimulate adrenal development and

corticosterone production/release with daily exogenous adrenocorticotropinstimulating hormone (ACTH} injections indicates an adrenal dependence on POMC
peptides for normal development and function during adrenal maturation. WhHe
the original Pomc_1_ mice, bred on a mixed white-bellied agouti (A w;Aw) 129 genetic
background, had patchy alternations in their coat color, they clearly were not a
uniform yellow like the lethal yellow (AY/a) mice. Our Pomc_1_ mice bred onto the
C57BL/6 (a/a) genetic background had a black coat color indistinguishable from
that of the wild-type C57BL/6 mice, further suggesting that the POMC peptide
melanocyte-stimulating hormone (a-MSH) is not essential for the production of
eumelanin (black/brown) pigmentation.
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2.

INTRODUCTION

Over the last ten years, the role of POMC peptides as central regulators of energy
homeostasis has become very apparent (Elmquist, Elias et al. 1999). Early evidence
centered on the detection of MSH binding to hypothalamic nuclei involved in regulating
energy homeostasis (Tatro 1990). Since then, a variety of mutant mouse models have
shown central aMSH to be an anorexigenic peptide, whereas the POMC opioid,

~

endorphin may play a more complex role in a reward pathway that reinforces feeding
behavior [Huszar, 1997 #56;Butler, 2000 #62;Chen, 2000 #!;Appleyard, 2003
#48;Hayward, 2002 #49]. In addition to the energy homeostatic role of central POMC
peptides, a large body of evidence exists implicating central POMC involvement in stress
response, reproduction, and ontogeny of the hypothalamus, pituitary and adrenal glands
(Allen, Pintar et al. 1984; Zag on and McLaughlin 1987; Estivariz, Carino et al. 1988;
Estivariz, Morano et al. 1988; Berry and Haynes 1989; Marsh, Hollopeter et al. 1999;
Bicknell, Lomthaisong et al. 2001).

However, further experiments are needed to

conclusively establish these hypothesized roles of central POMC peptides from other
peptidergic systems. Additionally, in vivo experiments using a POMC transgene are
described in later chapters that help delineate the roles of central POMC peptides from
those of peripheral POMC peptides released from the pituitary gland corticotrophs and
melanotrophs. This chapter identifies specific physiological alterations in the Pomc_1_
mutation on the C57BL/6 murine genetic background.
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3.

ORIGINAL POMC NULL MUTATION

A mouse strain, deficient in all POMC peptides, was generated by the Hochgeschwender
and Brenan laboratories using homologous recombination of a replacement-type Pomc
allele containing a deletion of exon 3 and insertion of neo (see Figure 2; chapter 1). This
mutant strain was generated on a mixed white-bellied agouti 129 genetic-background
(Aw/A w pTy rclpTyrC-Ch) and develops hyperphagia and obesity similar to that seen in the
lethal yellow (AY!a) mice and MC4-R deficient mice (Yaswen, Diehl et al. 1999).

However, in contrast to these and other previously described obesity models, Pomc_1_
mice have no detectable levels of circulating corticosterone or epinephrine. Analysis of
adult suprarenal fat pads revealed what appeared to be an adrenal remnant but no clearly
identifiable adrenal glands. A possible result of the adrenal absence was the partial
perinatal lethality seen in offspring of heterozygous breeder pairs. The loss of circulating
a -MSH, the MCl-R agonist, was predicted to eliminate the production of eumelanin
(black/brown) pigmentation in melanocytes of the Pomc_1_ mice; however, they had only
modest increases in phaeomelanin (yellow) pigmentation, most noticeable on their
bellies.
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4.

INCREASED ADIPOSITY AND LINEAR GROWTH

To better understand the contribution ofPOMC peptides to hair follicle pigmentation, we
backcrossed the Pomc_1_mutant allele from the agouti (Aw/Aw) 129 genetic background on
to the C57BL/6 (ala) genetic background for two successive generations. Additionally,
the C57BL/6 genetic background allows us to study proposed POMC physiological
functions on a more commonly used inbred mouse line and one that is predisposed to
diet-induced obesity, thus eliminating confounds due to genetic heterogeneity when
comparing data to the melanocortin receptor knockouts and other spontaneous mouse
obesity models.

Analysis of growth curves of Pomc_1_ mice (Figure 1) reveals an increase in body mass
very similar to that seen in the lethal yellow (AY!a) and MC4-R deficient mice. Further
analysis showed that the increased size of the Pomc_1_ mice was due to both an increase
linear growth and increased mass of white fat depots, again similar to those of the lethal
yellow and MC4-R deficient mice (Boston, Blaydon et al. 1997; Huszar, Lynch et al.

1997). There were no obvious differences in the growth curves of Pomc_1_ mice on the
129 versus C57BL/6 genetic background. However, all murine mutant models besides
the Pomc-1- mice have circulating glucocorticoids. In addition, when the lethal yellow or
the leptin-deficient ob/ob mice are adrenalectomized, these mice loose a significant
amount of their white-fat mass, suggesting that glucocorticoids play a significant role in
the development of obesity in these mutant mouse models (Boston, Blaydon et al. 1997).
Pomc·l- mice develop an obesity phenotype in the absence of circulating glucocorticoids.
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Figure 1
Male and female mice were group housed, fed a standard diet of rodent chow (5%
fat, 19% protein, and 5% fiber weight; 3.4kcal/g), and weighed monthly. Porne· 1•
mice became significantly heavier than wild-type littennates at 6-8 weeks old for
males and 4-6 weeks old for females. Heterozygous males developed later onset
obesity at about 8-1 0 months, whereas heterozygous females had a smaller

.
. b ody mass at 8- 10 month s. (0 , p orne-/- ;
mcrease
m
25 to 105.)
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suggesting a role for POMC peptides regulating energy homeostasis independent of
corticosterone.

5.

ADRENAL ATROPHY AND HORMONE DEFICIENCIES

The adrenal gland, composed of an outer cortical shell and an inner medullary core,
secretes the steroid hormones corticosterone, aldosterone, and androgens together with
the catecholamines: norapinephrin and epinephrine. Although the Pomc-!- mutant mice on
the 129 genetic background fail to develop any distinguishable adrenal glands, the
C57BL/6 mutant mice have easily identifiable, but severely hypoplastic adrenals. Pomc_1_
mice adrenal glands were approximately 15% (in females) to 30% (in males) the weight
of their respective wild-type littermates (Figure 2). The greater reduction in the size of
female adrenal glands compared with male adrenal glands eliminates the sexual
dimorphism found in wild-type mice. Morphological analysis of paraffin embedded
adrenal sections revealed an attenuated, dystrophic cortical layer possibly due to the
absence of ACTH stimulated glucocorticoid production (Figure 3). Adrenal cells that
synthesize and release glucocorticoids are localized in the zona fasciculata of the cortex.
The zona fasciculata in the Pomc_1_ adrenals had less eosin staining and the cellular
columns were more densely packed and less defined, again presumably a result of no
glucocorticoid synthesis and cytoplasmic storage. The Pomc_1_ mouse was originally
reported to lack detectable circulating epinephrine; yet, immunohistochemistry revealed
an attenuated medulla that was immuno-positive for tyrosine hydroxylase (TH).
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Figure 2
Adrenals were removed, trimmed of fat, and weighed as a pair from each mouse.
Male Pomc_1_mice adrenals were 70% smaller than those from their wild type and
heterozygous littermates. Female Pomc_1_ mice adrenals were 85% smaller than
those from their wild type and heterozygous littermates. In addition, female
Pomc+l-

heterozygous mice adrenals were slightly, but significantly, smaller than

those from wild type littermates. (***P <0.0001 and ** P <0.01 compared to
wild-type; N= 5 to 15.)
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Figure 3
Paraffin embedded male adrenal glands from Pomc+t+ and Pomc_1_ were sectioned
and stained with hematoxylin and eosin for morphological analyses along with
immunohistochemistry for tyrosine hydroxylase (brown reaction) in the medulla.
(A) At a magnification of I OX the smaller sized null adrenals still contain a
distinguishable adrenal cortex and medulla. (B) Higher magnification of the
cortex shows an attenuated and dystrophic cortical layer. Eosin, a dye staining
cytoplasmic material, seems to be less abundant in the null cortex. In addition,
the defined cell columns seen in the zona fasciculata (ZF) of wild type adrenals
are less defined and the cells are more densely packed.

(C)

Immunohistochemistry for tyrosine hydroxylase (brown reaction product) can be
seen in the medulla of both wild type and null adrenals. The cortex was counterstained with methelyne blue.
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The presence of tyrosine hydroxylase suggests a disruption in catecholamine production
downstream of TH. Despite the presence of these hypoplastic adrenals on the C57BL/6
genetic-background, plasma collected from unstressed, and restraint-stressed, or LPSchallenged Po me -I- mice still have no detectable levels of corticosterone (data not shown).
Furthermore, treatment of Pomc_1_ mice with exogenous ACTH (1-24) twice daily for 2
weeks failed to elicit any corticosterone secretory response, whereas wild-type responded
promptly to the same dose of exogenous ACTH 3 hours after dexamethasone suppression
of their HP A axis (Figure 4). The adrenal deficiencies in these mice strengthen the
hypothesis that normal POMC expression is needed for complete adrenal maturation;
however, the role of NHrterminal peptides in addition to ACTH remains an open
question (Bicknell, Lomthaisong et al. 2001).

We hypothesize that the lack of adrenal hormones, and not POMC peptides per se, is
responsible for the non-Mendelian production of viable Pomc_1_ offspring (Figure 5).
Both heterozygous and homozygous male and female mice were shown to be fertile.
Further evaluation ofheterozygous breeder pairs revealed that transmission of the Pomc_1_
allele was nonnal but that 50-70% of the homozygous Pomc_1_ mice die in the perinatal
period, typically within the first hour after birth. Homozygous breeder pairs produced
full-term litters with no pup surviving the perinatal period. Mice lacking corticotrophinreleasing hormone (CRH) are also unable to make corticosterone and exhibit a similar
perinatal lethality (Muglia, Jacobson et al. 1995). The CRH-1-lethality can be rescued by
administration of glucocorticoids to the mother's drinking water. However, an identical
attempt to rescue the lethality in the homozygous Po m c-l- breeder pairs proved
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Figure 4

EDT A-plasma corticosterone levels were measured usmg a

125

1-labeled

corticosterone radioimmunoassay kit from ICN. Dexamethasone (10 !kg/mouse)
was given i.p. immediately following blood draw at baseline time point A. At all
other time points, mice received either saline or 1 !lg ACTH (1-24) i.p., 30 min
prior to blood collection from a tail vein. All null male mouse EDTA-plasma
samples were 2X aliquot volume in order to lower the RIA detection level from
25 ng/ml to 12 ng/ml for these samples, yet at all time points the null plasma
samples were still below the assay sensitivity (12 ng/ml). (A) Dexamethasone
injection (time 0). (B) 2.5 h after dexamethasone (saline or ACTH injection). (C)
3.0 h after dexamethasone and 30 min after saline or ACTH. (D) 7 days after
twice daily ACTH injections (1 !kg/injection). (E) 14 days after twice daily
ACTH injections (1 !kg/injection). N

=

values at point A, Fisher's PLSD.
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2 to 6; ***P <0.001 compared to baseline
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Figure 5

Offspring numbers and percentages of total offspring for each genotype are
shown for two types ofbreeder pairs: heterozygous Pomc+l- male X heterozygous
Pomc+l- female, and homozygous Pomc·l- male X heterozygous Pomc+l- female.

The latter breeding pair was used to help generate sufficient numbers of Pomc·lmice for our experiments.
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Figure 5

Breeder Pair:
Offspring:
Number:
Percentage:

(+/-)X(+/-)
{±/.±)
{±/.:-)
{:-!:-)
83
158
31
30.5% 58.1%
11.4%

Breeder Pair:
Offspring:
Number:
Percentage:

(-/-)X(+/-)
{±/.±)
{±/.:-)
{:-/.:-)
0
93
27
0%
77.5% 22.5%

unsuccessful suggesting the Pomc·l- perinatal lethality may be a result of the combined
lack of glucocorticoids and epinephrine in the Pomc·l- pups. Pomc·l- pups expressing a
transgene that rescues pituitary POMC peptides and therefore adrenal corticosterone and
presumably epinephrine production, but that are still void of central POMC peptides do
not exhibit the perinatal lethality of their Pomc·l- siblings. These mice are described in
further detail in chapters 4 and 5 of this thesis.

6.

PIGMENTATION IS UNALTERED IN THE C57BL/6 GENETIC
BACKGROUND

Information gained from the recessive yellow (Mclre !Mclre) and the autosomaldominant lethal yellow (AY!a) mice would predict an inability to make eumelanin
pigmentation in the Pomc·l- mice (OHmann, Lamoreux et al. 1998). This prediction for
the Pomc·l- mice is based on the absence of stimulation of the MCl -R by its natural
POMC peptide agonist, a-MSH. In the lethal yellow mice, the constitutively activated
expression of agouti peptide antagonizes the MCl-R, preventing stimulation by aMSH
and inhibiting eumelanin synthesis. The original Pomc·l- mice on an agouti (Aw/A w) 129
genetic background resulted in only subtle alteration of yellow hair pigmentation on the
belly, much different from the coat color seen in the lethal yellow (AY!a) mice. The
presence of agouti in the 129 genetic background produces a banded hair shaft with both
eumelanin and phaeomelanin pigmentation, complicating the analysis of coat color on
this genetic background. To more closely evaluate the potential alterations in coat color
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in absence of peripheral aMSH, the Po me·'· allele was evaluated on an agouti-less genetic
background, C57/BL/6 (ala), to eliminate all phaeomelanin caused by antagonism of
aMSH binding. Our studies show no distinguishable difference in Pomc·l- black coat
color from wild-type (Po me+!+) or heterozygous (Po me+!") littermates on the C57BL/6
background, including the presence of a few yellow hairs behind the ears, in the perianal
area and around the female nipples seen on wild type C57BL/6 mice.

Possible

explanations for the black coat color in the absence of aMSH include endogenous basal
activity of MCl-R, compensatory pathways that stimulate cAMP production and
tyrosinase activity, thereby bypassing the MCI-R altogether, and alternative endogenous
agonist ligands for the receptor.

7.

POMC NEURONS, CORTICOTROPHS, AND MELANOTROPHS ARE
STILL PRESENT IN Pomc·l- MICE

The inability to immunohistochemically detect POMC cells in Pomc·l- mice makes it
difficult to know if the cells, void of the POMC peptides, are still present. To identify
and study POMC neurons in vivo, we previously generated a transgenic C57BL/6 mouse
line expressing enhanced green fluorescent protein (EGFP, Clontech) under the
transcriptional control of POMC genomic regulatory elements (Cowley, Smart et al.
2001). The transgene was designed to only express EGFP under the Pomc promoter, but
not to express any of the POMC peptides. We backcrossed this POMC-EGFP trans gene
onto the Pomc·l- mice to determine if the POMC neurons and POMC pituitary cells
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developed in their normal numbers and locations. Our analysis revealed that POMC
neurons along with pituitary corticotrophs and melanotrophs remain intact in the Pomc_1_
mice (Figure 6). POMC neurons have been found to co-express another peptide called
cocaine-amphetamine-response-transcript (CART), however, no other peptide has
beenshown to co-expressed in corticotrophs and melanotrophs with POMC peptides
(Elias, Lee et al. 1998). Whether CART neuron physiology has been altered and/or
whether pituitary corticotrophs and melanotrophs void of POMC peptides have any
physiological function in the Pomc_1_mouse has yet to be determined.

8.

DISCUSSION

The heterogeneity found among the many inbred mouse lines can result in an epistatic
modification of phenotypes when the same genetic mutations are analyzed (Butler and
Cone 2002; Kozak and Rossmeisl 2002). Therefore, the back-crossing and analysis of
the Pomc-1- allele are essential for understanding the function of the POMC peptides on
the C57BL/6 genetic background, an inbred strain that has been used for functional
analysis of melanocortin-receptor-deficient mice and other spontaneous obesity models.
In addition, C57BL/6 mice are sensitive to diet-induced obesity and have been the subject
of extensive behavioral and energy homeostatic studies. Although much of the data
originally obtained from the mutant POMC allele on the 129 genetic background has
been recapitulated in the C57BL/6 genetic background, we have found certain
discrepancies in the phenotypes. Most notably, we find that the coat color of Pomc_1_ on
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Figure 6

(A) Coronal vibratome sections (50-!-tm thick) from a compound Pomc-1-, PomcEGFPTgl+ mouse were viewed under UV light at lOX magnification on a Zeiss

microscope with a FITC filter cube. Neurons expressing EGFP are brightly
fluorescent and distributed in the arcuate nucleus of the basal hypothalamus in the
same location as POMC neurons. (B) A pituitary section (I 2!-tm) exhibiting
robust fluorescence in the intennediate lobe (IL) and the anterior lobe (AL) under
UV light at 3X magnification. Fluorescent cells seen in both intennediate anterior
lobes closely resemble those seen in melanotroph and corticotroph distributions.
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the C57BL/6 background is indistinguishable from that of wild type littermates. In
addition, we find that the adrenals are present in adult Pomc_ 1_ mice on the C57BL/6
background, although they are very much reduced in size and still incapable of secreting
corticosterone or responding to exogenous ACTH stimulation.
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CHAPTER IV

PITUITARY REPLACEMENT OF
PROOPIOMELANOCORTIN ON THE NULL
BACKGROUND AUGMENTS OBESITY THROUGH
METABOLIC SUPPRESSION AND HYPERPHAGIA
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1.

ABSTRACT

Null mutations of the proopiomelanocortiin gene (Pomc_ 1_) lead to obesity, but a
definitive contribution of hypothalamic versus pituitary POMC peptide-deficiency
hn its pathogenesis has not been established. Obesity syndromes due to mutations of

the melanocortin receptor-4 (MC4-R), which is only expressed in the central
nervous system, support a principal role of hypothalamic POMC and modulation of
neuronal circuits. However, it is possible that a loss of pituitary POMC contributes
iindependentlly to altered energy balance either directly through peripheral actions
of melanocortins or indirectly by the absence of ACTH, and secondarHy of
corticosterone, itself a potent regulator of metabolism and energy partitioning. Here
we demonstrate that obese Pomc_,_ mice backcrossed for two generations on the
C57BL/6 genetic background were actually hypophagic when food intake was
corrected for metabolic mass and they had decreased basal V0 2 consumption
measured by indirect calorimetry. To decipher the roles of hypothalamic versus
pituitary POMC, we generated Pomc_,_ mice expressing a transgene (Tg) with a
tissue-specific promoter that rescued production of all POMC peptides specificallly
in pituitary cells, and consequently adrenal glucocorticoid secretion, but which were
stm devoid of central POMC peptides (Pomc_ 1_; Tgl+). The replacement of pituitary
POMC markedly augmented body weight and white adipose tissue mass with a
disproportionate increase of subcutaneous fat in both sexes and exacerbated glucose
intolerance, particularly irn females, compared to Pomc_,_ mice. There were further
significant reductions in basal metabolic rate and increases in absolute caloric
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intake in both sexes, however food consumption corrected for metabolic mass was
normalized to wild-type levels only in the male Pomc-1-; Tgl+ mice. These data
confirm that hypothalamic POMC plays a criticali role in energy homeostasis and
pituitary POMC replacement carnnot compensate for the absence of central llleural
POMC peptides. In fact, the exacerbation of obesity and diabetes secondary to
insulin-resistance by a selective rescue of pituitary POMC expression indicates a
cournter-regulatory involvement relative to central POMC in the complex regulation
of energy homeostasis and partitioning, most likely mediated by ACTH-dependent
corticosterone secretion.

101

2.

INTRODUCTION

Due to the growing prevalence of obesity within affluent societies during the last quarter
century, understanding the underlying mechanisms of energy balance has become a
health-care priority (Isomaa 2003). Recently, a gamut of studies have established that
energy homeostasis is maintained by peripheral signals informing the central nervous
system (CNS) of energy storage levels and metabolic status. Peripheral information
processed centrally is then used to elicit the appropriate feeding and/or metabolic
response.

Hormones like leptin, insulin, and corticosterone relay this peripheral

information to hypothalamic nuclei that in tum regulate energy consumption, utilization,
and storage.

One of these nuclei, the arcuate nucleus of the hypothalamus, contains neurons
expressing the gene encoding the prohormone proopiomelanocortin (POMC). POMC is
post-translationally processed to the melanocortin peptides-adrenocorticotropin
stimulating hormone (ACTH), a-melanocyte stimulating hormone (a-MSH), and 'Amelanocyte stimulating hormone ('A-MSH)-and additionally the endogenous opioid,

~

endorphin. Recently, our laboratory demonstrated that these POMC neurons in mouse
hypothalamic slices could be activated by the adipocyte-generated hormone, leptin
(Cowley, Smart et al. 2001 ). In addition, genetic disruption of the mouse or human
POMC genes gives rise to early-onset obesity (Krude, Biebermann et al. 1998; Yaswen,

Diehl et al. 1999). Furthermore, mutations of melanocortin receptor-4 (MC4-R), the
most abundant melanocortin receptor expressed in the central nervous system (CNS), also
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lead to both mouse and human obesity (Vaisse, Clement et al. 1998; Yeo, Farooqi et al.
1998). Such findings identify POMC neurons as a critical anorexigenic component in the
hypothalamic peptidergic-pathways that regulate energy homeostasis.

While the majority of studies have focused on POMC's central roles in energy
homeostasis, a complete understanding of pituitary POMC's role in energy balance has
not conclusively been established. The POMC null mouse (Pomc_ 1_) does not reveal
whether pituitary POMC plays a role in energy homeostasis or whether this homeostatic
role is exclusively a function of hypothalamic POMC neurons. By transgenic rescue of
only pituitary POMC in the Pomc_,_ background, we are able to address this question.
The fact that the Pomc_,_ mice develop obesity in the absence of circulating
glucocorticoids, which are present and sometimes elevated in known obesity models,
emphasizes the role of hypothalamic POMC in weight regulation. However, as we report
in this paper, the replacement of pituitary POMC, and thus glucocorticoids, has profound
effects on energy balance beyond what is seen in the Pomc_,_mice.

3.

METHODS

Transgene construction. A 10.2 Kb mouse genomic clone containing all three POMC
exons was used to construct the POMC rescue transgene pHalEx2*. This genomic clone
contains 2 Kb of 5' and 1.5 Kb of 3' flanking regions, the essential DNA elements
needed for pituitary-specific expression, but does not contain the regulatory elements for
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directing hypothalamic expression ofthe POMC gene (Rubinstein, Mortrud et al. 1993).
A

patr

of

complementary

23

bp

oligonuc leotid es

(5'-

CCCGGGCTCGAGTTTAAAGCGCG-3' and 5'CGCGCTTTAAACTCGAGCCCGGG3 ') was synthesized, annealed to form a blunt-ended double stranded DNA fragment, and
inserted at the Stu I site in the 5' untranslated region of ex on 2 by a ligation reaction. The
inserted oligo was designed to detect transgene expression independently of the
endogenous POMC alleles but not interfere with translation of POMC from mRNA.
Additionally, the following restriction-enzyme sequences were introduced into exon 2 by
the transgene oligo: Srjl, Smal, Xhol, Dral, and BssHII. These restriction-sites were used
for distinguishing PCR products obtained from wild type and transgenic alleles. In
addition these sites will facilitate the introduction of additional sequences by directed
ligations into new transgenes based on the Pomc genomic regulatory elements.

Care and use of animals. A colony of Pomc mutant mice was established as described
previously (Smart and Low, 2003). Pituitary Pomc-Tg mice were generated by nuclear
microinjection of the linearized, oligonucleotide marked pHalEx2* Tg into B6D2 F2
hybrid embryos using standard techniques (Brinster and Palmiter 1984). The pHalEx2*

Tg allele was backcrossed to the C57BL/6 genetic background for two generations and
subsequently crossed onto the Pomc_1_ genetic background by an additional two
generations of heterozygous matings. Therefore the hybrid genetic background of mutant
mice used in these experiments was approximately 80% C57BL/6, 10% DBA/2, and 10%
129. All animals for these studies were maintained under controlled temperature and
photoperiod conditions (14 h of light, 10 h of dark; lights on, 0500 h) with food and water
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provided ad libitum except for overnight fasting studies. All surgical procedures and
other experimental studies were approved by the Institutional Animal Care and Use
Committee and followed the guidelines established by the Public Health Service.

Genotyping. PCR genotyping was conducted on DNA extracted and prepared from tail

clippings (described in (Barnes 1994)). Touchdown PCR was used to favor amplification
of desired amplicons and to limit artifactual amplicons and primer-dimers (protocol
described in (Don, Cox et al. 1991)). Multiple cycles were programmed so that the
annealing segments in sequential cycles are run at incremental lower temperatures
starting at the suspected melting temperature (Tm). To avoid low-Tm priming during the
earlier cycles it was imperative to apply a hot start modification to the PCR protocol
(D'Aquila, Bechtel et al. 1991). The programmed PCR cycle was 94·c for 10min; [94"C30sec; 64·c minus 1·c per cycle-30 sec; 72.C-30 sec] X 15 cycles; [94.C-30sec; 5o·c30 sec; 72.C-30 sec] X 15 cycles; 72"C-3min; hold at 4·c. Three separate reactions were
required to identify all three alleles: wild type, null, and transgenic. Wild type allele
primers identified as POMWF (5'- GCTTGCATCCGGGCTTGCAAACT-3') Tm=68·c
and POMWR (5'-AGCAACGTTGGGGTACACCTTC-3') Tm=72·c gave a 317 bp
product.

Null

allele

primers

identified

TTGTTAACTTGTTTATTGCAGCTT-3') Tm=57"C

as
and

POMMF

(5 '-

POMMR

(5'-

ATGAGAAATTGGGCCATGGGACTGAC-3') Tm=73·c gave a 210 bp product.
Trans gene

allele

primers

identified

TAGTGTTGGCTCAATGTCCT-3') Tm=53 · c

as

POMC

Ex2

Sense

(5 '-

and POMC Ex2 Antisense (5'-

GCTCTCCAGGCACCAGCTCC-3') Tm=63·c gave a 230 bp product from the
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endogenous gene and 226 bp product from the transgene containing the inserted 253 bp
oligonucleotide. A standard PCR reaction mix was used as described in the manual
"PCR Primer" (Dieffenbach and Dveksler 1995).

In situ hybridization. mRNA in-situ hybridization was performed utilizing the antisense

strand of the inserted 23 bp oligonucleotide as the radio labeled probe, to confirm that the
transgene was expressed in a normal pattern in the pituitary but not the hypothalamus of

F1 transgenic mice (data not shown). After crossing the transgene onto the Pomc null
background, additional in situ hybridization experiments were performed with a single
stranded RNA probe for Pomc mRNA, further confirming appropriate expression of the
pHal Ex2* transgene in the pituitary and not the hypothalamus (see chapter V).

Histology and immunohistochemistry. Mice were anesthetized and perfused with 4%

paraformaldehyde to provide tissue fixation for histological analyses. 50 !liD sections of
brain and pituitary were collected with a vibratome.

Immunohistochemistry was

conducted as previously described using rabbit polyclonal antisera for B-endorphin or
ACTH (Cowley, Smart et al. 2001) followed by biotinylated goat anti-rabbit serum, ABC
Elite avidin-biotin-peroxidase complex

(Vector Labs, Burlingame, CA), and

diaminobenzidine (DAB) for the reaction product.

Growth charts, length, and tissue weights. Male and female mice of mixed genotypes

were group housed, fed a standard diet of rodent chow (5% fat, 19% protein, and 5%
fiber by weight; 3.4 kcal/g), and weighed weekly for 6 months. At 9 months final
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weights were obtained and nose to anus lengths measured, then the mice were sacrificed
and tissues dissected and weighed individually (liver, spleen, thymus, and heart) or in
pairs (fat depots, adrenals, kidneys, and gonads).

Fasting glucose, insulin and leptin. Following a 24-hour fast, glucose was measured

from tail blood using an Accuscan glucometer. Insulin and leptin levels were measured
using EDTA-plasma with mouse-specific leptin and insulin RIAs (Linco, Inc.) according
to the manufacturer's instructions. Even with a two-fold dilution of plasma samples,
most values for Pomc_1_; Tg/+ males and females and occasional values for some of the
other genotypes were above the highest concentration of the standard curves in both
RIAs. Therefore to better estimate the real differences in these values from those in other
genotype groups that were clustered just at the highest standard concentrations (2 ng/ml
for insulin and 40 ng/ml for leptin), we manually re-plotted the standard curves onto
semi-log graph paper and extrapolated from these curves a higher cutoff point that clearly
delineated the populations of extreme outliers. All data points in these outlying clusters
were then reassigned values of either 4 ng/ml for insulin or 80 ng/ml for leptin prior to
statistical analysis. All other data points at or above the highest standard concentration
but below the extreme outliers were assigned values of 2 ng/ml for insulin and 40 ng/ml
for leptin.

Glucose tolerance test. Mice were fasted overnight 16-18 hours then given an i.p. bolus

of glucose (2g/kg as dextrose 300 mg/ml). Blood glucose was measured from tail blood
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using an Accuscan glucometer at 0, 10, 20, 30, 45, 60, 90, 120, 180 minutes postinjection.

Food consumption, basal metabolic rate, and respiratory exchange ratio. Mice 6-7

months old were individually housed, fed standard chow as previously stated, and the
chow was weighed daily for 14 days allowing 9 days of habituation to the stress of
individual housing and restabilization of feeding behavior. Food consumption was then
averaged across days 10-14 and normalized to metabolic mass using the scaling formula
[food intake (g)/body weight (g) /\0 ·75 x 100] (Pace, Rahlmann et al. 1980).

Basal metabolic rates were assessed using an indirect open-circuit calorimeter system
(Oxymax, Columbus Instruments) consisting of 8 chambers with dimensions of 10.5 em
(W) x 20.5 em (L) x 12.5 em (H) that limit spontaneous locomotor activity. Mice were
placed into individual chambers at 8:00AM for six hours without access to food or water
on two sequential days to allow for chamber habituation. Following habituation, a total
of 12 measurements were recorded from each mouse with approximately 30 minutes
between each measurement for a total experimental sampling period of 6 hours on the
third day. The inlet fresh air-flow rate was 0.5 1/min with a sample flow rate of0.41/min.
Each chamber was sampled for 50 s with a resting time of 150 s. Individual basal oxygen
consumption (V0 2) levels were established by averaging the three lowest of twelve V02
measurements. C02 production from each mouse was also recorded simultaneously and
used to calculate the respiratory exchange ratio (RER) [VC02N02] at each 30 min
interval.
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Statistics. Data were analyzed by 2-factor ANOVA using Stat View Power PC version

for Macintosh (version 5.0.1; SAS Institute Inc., Cary, North Carolina, USA) except
where otherwise stated. P values less than 0.05 were considered significant. Post hoc
comparisons between groups were performed by Fisher' s (PLSD).

4.

RESULTS

4.1

Transgenic rescue ofpituitary POMC in Pomc null mice

The original Pomc_1_ knockout mice were generated on a hybrid white-belled agouti 129
genetic background (A w/Aw; pTyrclpTyrc-ch) using homologous recombination to replace
exon 3 with a neomycin cassette thus deleting the coding region of all known functional
POMC peptides (Yaswen, Diehl et al. 1999). We backcrossed the Pomc- allele for two
generations onto the non-agouti, wild-type tyrosinase C57BL/6 (ala) background to
evaluate possible epistatic contributions to phenotype (Smart and Low 2003). By
backcrossing onto the C57BL/6 genetic background, an inbred mouse line more
commonly used in energy homeostasis studies, we reduced the genetic heterogeneity
when comparing our data with those of other spontaneous or genetically induced mouse
obesity models. To replace pituitary POMC expression in the Pomc_1_ background, we
generated a strain of transgenic mice (pHalEx2*) utilizing previous promoter mapping
studies that identified critical DNA flanking regions essential for expression of the Po me
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gene in the pituitary but not in hypothalamic neurons (Rubinstein, Mortrud et al. 1993). A
23 bp oligonucleotide was inserted into the untranslated region of exon 2 thus allowing
identification of the transgenic allele from that of the other alleles. The wild type
1

1

(Pomc+ +), null (Pomc- -),

andpHalEx2* transgenic (Tg) alleles are depicted schematically

in Figure 1.

Hemizygous pHalEx2* (Tgl+) transgenic mice and Pomc+l- mice were intercrossed to
generate Pomc+1-; Tgl + female breeders. These Pomc+1-; Tgl+ females were then bred
with either Pomc+l+ or Pomc_ 1_ males to generate Pomc+l+, Pomc+'-, and Pomc_,_ mice with
and without the trans gene (Tgl+) resulting in a total of six potential genotypes for both
sexes. Combinations of PCR reactions using primers specific for each allele identified
these six genotypes. Initially, mRNA in-situ hybridization with a transgene-specific
oligonucleotide probe was used to demonstrate selective expression of the transgene in
pituitary corticotrophs and melanotrophs but not in hypothalamic neurons (data not
shown). Immunohistochemistry on coronal brain and pituitary sections then confirmed
the restored production of POMC peptides P-endorphin (Figure 2) and ACTH (not
shown) in Pomc_1_; Tgl+ pituitaries but not hypothalami.

4.2

Effects on adrenal size, body weight, body length, and white adipose
tissue by pituitary Pomc rescue in Pomc null mice

The transgenic rescue of pituitary but not hypothalamic POMC restored adrenal function,
demonstrated by a reversal of adrenal atrophy (Table 1) and production and secretion of
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Figure 1
Schematic of wild type Pomc+1+, null Pomc·1-, and transgene pHalEx2* (Tgl+)
alleles are shown with a neomycin cassette replacing exon 3 in the Pomc·l- allele
and a 23 bp oligo inserted into exon 2 indicated by(*) in the pHal Ex2* (Tgl+)
allele. The arrow (shown above exon 1) represents the transcriptional start site.
PCR primers used described in the Methods are indicated by the red arrows.
Wild type allele primers set A,B

=

(317 bp product); Null allele primer set C,D =

(210 bp product); and Pomc Tg allele primer set E,F
bp trans gene products)
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=

(230 bp wild type or 253

Figure 1

POMC alleles
Wild type
(Pomc +I+)
A

...
~

B

Exon 1

Exon2

Exon3
lKb

Null
(Pomc -/-)

c

......

pHalEx2*
(Tgl+)

Figure 2

Immunohistochemistry for

~-endorphin

in sections of hypothalami and

pituitaries. The POMC peptide ~-endorphin was detected in (A) Pomc+l+ but not

(B) Pomc·l- or (C) Pomc·1·; Tgl+ hypothalami.

~-endorphin expression was

detected in (D) Pomc+l+ and (F) Pomc·1-; Tgl+ but not (E) Pomc·'- pituitaries
confirming rescued peptide expression from the pHa! Ex2 * transgene on the
Pomc·l- background in pituitary but not hypothalamus.
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Figure 2
Hypothalamus
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B)

A)

ArcN

'

Pomc -1-

Pomc +I+

Pomc -1-; Tg/+

Pituitary
D)

F)

E)

Pomc +I+

Pomc -1-

Pomc -1-; Tg/+

Table 1

Wet tissue weights of mice sacrificed at 9-11 months old
Male
Genotype (n)
Pomc+1+; +I+ (5)
Pomc+l+; Tgl+ (3)
Pomc+'·; +I+ (11)
Pomc+'·; Tgl+ (10)
Pomc·'·; +I+

(6)

Pomc.f·; Tgl+

(9)

Liver (g)
1.5 :t .1
1.8 :t.2

2.5
2.9
4.1
6.9

:1: .2
:1: .4 "
:t .5 b
:t .5 r

Spleen (mg)
89 ±8

88
95
98
256
164

±7
:t6
±8
±16'.
:t 7 r

Thymus (mg)
22 ± 3
27 ±3

22
23
28
27

±1
±1
±2"
:t3

Kidney (mg)
466 :1:21

476
573
590
570
679

± 25
:1:43
:1:66
:t 46
:t 43 "

Heart (m~)
177 :t 17

Testes (mg)
232 :t8

174
200
212
224
238

234
228
225
232
214

:t 6
:t8
:t 18
:t 10"
:tIl l>

:t4
:1: 13
:tll
:t 13
:t 10

Main effect for genotype on weights of liver (F,,38 =22.2, p < 0.0001); spleen (F5,44=22.6, p < 0.0001);
thymus (F5,29 =2.1, p < 0.09); kidney (F 5,31 =1.7, p < 0.15); and heart (F 5,31 =3.1, p < 0.02). "p< 0.05; b p<
0.01; " p< 0.0001 compared to (Pomc+ 1+; +I+) Fisher's PLSD

Female
Genotype (n)
Pomc+'+; +I+ (7)
Pomc+'+; Tgl+ (5)
Pomc+'·; +I+
Pomc+1·;

(6)
Tgl+ (4)

Pomc·'·; +I+

(5)

Pomc·'·; Tgl+ (7)

Liver (g)
1.2 :t .1
1.3 :t .1

1.6 :1: .1
1.6 :t .I
2.3 :1: .3 "
4.8 ± .6 cl

Spleen (mg)
96 :t8

102 :t7
108 :1: 10
125 ± 16
227 :1: 21''
161 :1: 12
I

Thymus (mg)
22 :t3

20
16
21
31
18

:t2
:t1
:t4
:t 3 "
:t3

Kidney (mg)
347 :tll

357
371
376
404
467

± 4
:1: 13
:1:20
:t 30 b
:t 24 d

Heart (mg)
130 :t 17

139
139
145
181
211

:1: 5
±4
:t6
±12"
:1: 9 cl

Ovaries (mg)
8.8 :t 1.9
7.8 :t: 1.2

8.0
7.6
10.2
10.2

Main effect for genotype on weights of liver (F 5,28 =22.9, p < 0.0001); spleen (F5,28 =14.8, p < 0.0001);
thymus (F5,28 =3.2, p < 0.02); kidney (F5,2 8=6.2, p < 0.0006); and heart (F5,28=22.2, p < 0.0001). 'p<
0.05; hp< 0.01; "p< 0.001; dp< 0.0001 compared to (Pomc+i+; +/+)Fisher's PLSD

Values are the mean± SEM. Adrenal, kidney, testes and ovaries values are the mean of
tissue pairs.

Significant differences in means from that of Po me+I+; +I + m1ce are

indicated in the tables with corresponding p-values found beneath each table.
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±.6
± .7
± .4
:t.7

glucocorticoids. Unexpectedly, the adrenal glands in

1

Pomc__;

Tgl+ male and female

mice were significantly larger than their same sex wild type siblings, although basal
serum corticosterone levels were only significantly higher in

1

Pomc_ _;

Tgl+ males

compared to Po me+!+ males (data presented in Chapter V). Replacing pituitary POMC in
the

1

Pomc_ _

mice had profound effects to further increase their body weights, but

pHalEx2* Tg expression did not affect the weights of either Pomc+!+ or Pomc+l- mice
(Figure 3A). By age six months, both sexes of Pomc_1_; Tg/+ mice gained between 30%
to 40% more weight than their Pomc_1_ siblings. Significant separation of body weight
was observed between 4 to 6 weeks of age in both the
compared to

Po me+I+

1

1

Pomc_ _ and Pomc__;

Tgl+ mice

mice. Late onset obesity at 3 to 4 months of age was observed in

the Pomc+l- males while only a trend was evident in

Pomc+l-

females as previously

reported (Smart and Low 2003). The increase in body weight can partially be attributed
to an increase in linear growth in both sexes of Pomc+t- and Pomc_1_ mice; however, the
pituitary pHalEx2 * transgene had no effect on linear growth on any of the genotypes
except Po me+I+ females (Figure 3B). The fact that linear growth was not altered by the

pHalEx2* transgene indicates that it is the loss of hypothalamic POMC peptides, and not
pituitary POMC peptides that directly or indirectly affects linear growth.

Most of the differences in body weight among the genotypes were accounted for by white
adipose tissue. Analyses of white fat depots showed that the increased body weight
correlated with increased mass of white fat depots (Figure 4). Interestingly, gonadal fat
mass was largest in Pomc_1_ mice as compared to their Pomc_1_; Tgl + siblings, even though
the latter mice had body weights that were 30% to 40% greater. In fact, the gonadal fat
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Figure 3
The effects of rescued pituitary POMC expression on body weight and body
length in the Pomc_1_ background. (A) Body weight curves for male and female

Po me+!+, Po me+!-, and Po me·!- mice with and without the pHalEx2 *trans gene (n =
9-44). (B) Body lengths ofmale and female mice at age nine months (n = 3-12).
Data are reported as the mean± SEM. * p<O.Ol; ** p<O.OOI; *** p<O.OOOI
compared to (Pomc +!+; +I+), Fisher's PLSD.
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Figure 4

White adipose tissue depots from male and female Pomc+1+, Pomc+1-, and Pomc_ 1_
mice with and without pHalEx2 * transgene expression are shown as a box plot to
compare variable distributions. The box and whisker plots shows the lOth, 25 1\
501h (median), 75t11 , and 90th percentiles for renal, gonadal, visceral, and inguinal
white adipose tissue depots from mice 9 to 11 months old (n = 3-11). Values
above the 90111 and below the 10111 are plotted as points (0 ). Male inguinal adipose
tissue was not weighed. *p<0.05; ** p<O.Ol; *** p<O.OOOl compared to
1

(Pomc -r +;

+/ +),Fisher' s PLSD.
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Conversely, the mass of renal, visceral, and inguinal white fat depots in the Pomc_1_; Tg/+
mice was greater than that measured in the Pomc_1_ mice with the most striking difference
in subcutaneous fat. The inguinal fat pads, representative of subcutaneous white fat
deposits, were disproportionately larger in the female Pomc_1_; Tg/+ mice compared to the
other genotypes. Although we did not weigh intrascapular white fat, we observed that an
excessive amount of white fat had also accumulated dorsally in the Pomc_1_; Tgl+ mice.
These differences in subcutaneous white fat depots accounted for a significant portion of
the body mass differences between Pomc_1_; Tgl+ mice and their Pomc_1_ siblings. Liver
mass was also substantially increased with the visual appearance of fatty infiltration
(Table 1).

4.3

Pomc_1_ and Pomc_1_; Tg/+ mice exhibited type II diabetes that was more
pronounced in Pomc_1_; Tgl+ females

The markedly exacerbated obesity seen in the Pomc_1_; Tg/+ mice led us to evaluate the
possibility of associated endocrine abnormalities. Whole blood glucose measurements
obtained at random times from ad libitum feeding mice at 3 to 4 months of age showed
significantly higher levels of glucose in Pomc_1_ and Pomc_1_; Tg/+ males and Pomc_1_;

Tgl+ females (data not shown). At 6 months of age, mice were fasted overnight and
whole blood glucose, plasma insulin and plasma leptin levels were measured (Table 2).
Male Pomc+1-; Tgl+ and Pomc_1_; Tg/+ mice were hyperglycemic yet the females had
normal fasting glucose levels. Furthermore, male Pomc_1_; Tgl+ mice and female Pomc_1_
and Pomc_1_; Tgl+ mice were hyperinsulinemic. Predictably, hyperleptinemia was
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TABLE 2

Fasting glucose, insulin, and leptin levels in 6-8 month old mice
Male
Genotype (n)
Pomc+'+;(+/+)

(8)

Pomc+'+;(Tgl+)

(6)

Pomc+1-;(+/+)

(13)

Pomc+'-;(Tgl+)

(9)

Pomc--;(+1+)

(9)

Pomc_,_;(Tgl+)

(6-7)

Glucose (mgldl)
89 ±7
94 ±8
108 ±7
107 ±8
124 ±8 h
125 ± 13 h

Insulin (ng/ml)
0.73 ±.20
0.99 ±.30
0.86 ± .14
1.53 ±.20 "
1.15 ±.17
,.
2.91 ±.54

Leptin (ng/ml)
10.8 ± 2.3
26.3 ± 12.1
23.6 ±3.4
33.5 ± 3.7 b
26.7 ± 4.0
70.5 ± 9.5
l'

Main effects for genotype on glucose (F5,45 = 2.79, p < 0.05), insulin (F 5,46 = 8.97, p < 0.0001), and
Ieptin (F 5,46 = 11.3, p < 0.0001). "p< 0.05; bp< 0.01; ''p< 0.0001 compared to (Pomc+l+,. +/+)Fisher's
PLSD.

Female
Genotype (n)
Pomc+1+;(+/+)
Pomc +I+ ;(Tg/+)
Pomc+'-;(+1+)
Pomc+'-;(Tgl+)
Pomc+;(+l+)
Pomc- -;(Tg/+)

(12)
(8)

(22-23)
(11)

(4)
(12)

Glucose
83
78
85
88
95
89

Insulin (ng/ml)
0.46 ±.08
0.60 ±.20
0.36 ±.03
0.32 ±.06
0.93 ±.38 "
2.52 ±.33 c

_(mg/dl)
±5
±6
±6
±7
± 10
±6

Leptin
17.1
21.8
20.7
22.5
33.9
68.6

(n~/ml)

± 1.7
± 4.2
± 2.2
±3.4
± 2.1

"

6.1

r

±

Main effects for genotype on insulin (F5,64 = 27.6, p < 0.0001) and leptin (F 5,64 = 29.9, p < 0.0001).
·' p< 0.05; up< 0.01; "p< 0.0001 compared to (Pomc+1+; +/+)Fisher's PLSD.

Values are the mean± SEM. Significant differences in means from that of Pomc+1+; +/+
mice are indicated in the tables with corresponding p-values found beneath each table.
Some individual values above the highest concentrations of the RIA standard curves (2
ng/ml for insulin and 40 ng/ml for leptin) were extrapolated before statistical analyses as
described in the Methods.
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observed in genotypes of both sexes that had a significant increase in body weight and
white adipose tissue. Intraperitoneal glucose tolerance tests (2g/kg) were performed on
mice at age 6-8 months. Male Pomc+!- and Pomc_1_ mice with and without pHa!Ex2 *
transgene expression were equally impaired in their hyperglycemic responses to the
glucose challenge (Figure 5). Female Pomc+1-, Po me+!-; Tgl+, and Pomc_1_ mice all
exhibited a mild glucose intolerance, but this shift compared to Pomc+l+ mice was
overshadowed by the markedly abnormal glucose tolerance of Pomc_1_; Tgl+ female mice.
Unlike male Pomc_1_; Tg/+ mice, female Pomc_1_; Tgl+ mice were not hyperglycemic
following an overnight fast yet they exhibited profound impairment after a glucose
challenge.

4.4

Obesity in Pomc-1- and Pomc_1_; Tgl+ mice was due to distinct
combinations of altered basal metabolic rate and food intake

Mice 6 to 8 months of age were individually housed and food consumption was recorded
daily over a 14-day period. All mice exhibited an initial stress-induced hypophagia,
apparent on the first four to eight days of group separation (data not shown). Between
days 5 to 8, daily food consumption increased and a steady-state plateau was established.
Food consumed on days 10-14 was then measured and averaged for each mouse to
calculate daily food intake by all genotypes (Figure 6). Absolute daily caloric intake was
identical among male and female mice for all genotypes except for the Pomc_1_; Tg/+
mice, which consumed significantly more food than wild type siblings. The five-day
averages were also corrected for metabolic mass according to the formula [food intake
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Figure 5

Intraperitoneal glucose tolerance tests performed on 6 to 8 month old male and
female mice after a 16-18 hour fast (n = 4-24). For clarity, results from the
1

1

Pomc+ +; Tg/ + and Pomc+ -; Tgl+ groups are not shown but they did not differ

from their corresponding groups without the pHa! Ex2* trans gene (Tgl+) in either
sex. Data are rep01ied as the mean± SEM.
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Figure 5
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Figure 6

Average daily absolute food intake over five days for each mouse after nine days
of acclimation to individual housing (n=6 to 24). Food intake measurements are
shown as the absolute values. There were significant main effects of genotype for
male (F 5,57 = 19.9, p < 0.0001) and female (Fs,62 = 40.8, p < 0.0001) mice.
p<O.OOl compared to (Pomc+1+; +/+), Fisher's PLSD.
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00] (Pace, Rahlmann et al. 1980). In contrast to the values for

absolute food intake, both male and female Pomc_1_ mice and female Pomc_1_; Tg/+ mice
had significantly lower food intake normalized to estimated metabolic mass than their
wild-type siblings (Figure 7). Only the male Pomc_1_; Tg/+ mice had corrected food
intake values that were indistinguishable from wild type animals, although the mutant
males were clearly hyperphagic based on their absolute daily consumption of food.

To explain the maintenance of obesity in the mutant mice in the context of their measured
caloric intake, we next assessed their basal metabolic rates by indirect calorimetry.
Oxygen consumption (V02) was measured over a 6-hour period starting at 9:00 AM
during the animals' most inactive phase of the diurnal light-dark cycle. 12 measurements
were obtained from each mouse at 30 min intervals and the lowest three measurements
over the 6-hour period were averaged to estimate basal levels of oxygen consumption.
Basal V02levels were indirectly correlated to body weight differences among genotypes
for both male and female mice (Figure 8). An identical ranking of V0 2 levels by
genotype was obtained when all 12 measurements instead of the lowest three were used
in the calculations (data not shown). Furthermore, both male and female Pomc_ 1_; Tgl +
mice exhibited an elevated respiratory exchange ratio (RER), particularly in the earliest
of the 12 measurements, compared with the other three genotypes (Figure 9). A higher
ratio indicates less fatty acid oxidation and is indicative of a shift in the type of energy
stores utilized and possibly a shift in energy partitioning (Elia and Livesey 1992).
1

Pomc+ +;

Tgl + and Pomc+1-; Tgl + mice were not analyzed in the Oxymax chambers.
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Figure 7
Average daily food intake as shown in figure 6 that has been corrected for
metabolic mass with the following formula [5 day average of food intake (g) I
body weight (g)"0 -75 *100]. There were significant main effects of genotype for
male (F 5, 57 = 2.7, p < 0.0285) and female (Fs,62 = 7.6, p < 0.0001) mice.
p<O.Ol;

*** = p<O.OOl compared to (Pomc+1+; +/ +),Fisher's PLSD.

129

**

=

Figure 7
Male
35

=
=
~

25
**

*
r-..

Ill

=

,-....

~

.... 15
..=
~
'-'

·-~

Genotype
•
•
•

~

~

Female

0

~
~

35

0
D
D

~

'-'
a,)

~

....
~

=

~

~

***

25

(+1+)1( +1+)
(+I+)I(Tgl+ )
(+1-)1(+1+ )
(+1-)I(Tgl+)
(-1-)1(+1+)
(-1-)I(Tgl+)

***

0
0

~

15

Genotype
** p< 0.01; *** p< 0.001

Figure 8

Basal metabolic rate measured by volume of Oz (VOz) consumption corrected for
body weight (ml/kg/hr) in Oxymax chambers. Data shown are the means± SEM
ofthe three lowest measurements from each mouse (n = 5-10) over approximately
a 6-hour period. There were significant main effects of genotype for male (F 3,21
8.8, p < 0.0006) and female (F 3,23 = 24.7, p < 0.0001) mice.
p<O.OOOl compared to (Pomc+1+; +/+),Fisher's PLSD.
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Figure 9

Respiratory exchange ratio (RER) was higher in both male and female Pomc_ 1_;
Tg/+ mice compared to Pomc+1+; +/+ siblings. For clarity, results from the
1

Pomc+ -;

+I+ and Pomc_1_; +/+ groups are not shown but they did not differ from

their Pomc+1+; +I+ siblings.

Each time interval on the horizontal axis is

equivalent to 30 minutes. There were significant main effects of genotype by a
repeated measures ANOVA for male (F

3,21

19.1, p < 0.0001) mice.*= p<0.05; **

p<0.0001; Fisher's PLSD.
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=

= 2.9, p < 0.0614) and female (F 3,23 =
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normalization of food intake to metabolic mass using the conventional scaling exponent
of mass to the three fourths power originally proposed by Kleiber (Kleiber's law), the

Pomc_1_ mice actually appeared to be hypophagic and hence more efficient in caloric
utilization than their wild-type siblings. Estimates of basal metabolic rate by the
measurement of V02 consumption were consistent with this contention and showed a
20% decrease compared to wild type siblings. Importantly, preliminary results of food
intake and V02 consumption obtained from another cohort of mice at age 6 wk, when
body weights are much more similar among genotypes but the rate of weight gain is at its
maximal slope, showed the same pattern of comparable absolute daily food intake but
decreased metabolic rate of Pomc_1_ mice compared to Pomc +I+ mice (data not shown). It
is possible that the differences between our results and those of Yaswen, et al. (1999)
regarding food intake are a reflection of the different genetic background of the mutant
mice in each study. Whereas the other laboratory maintained the Pomc_1_ allele on an F2
129 hybrid background, the mice used in our experiments had a predominant C57BL/6
background.

Adipocytes are no longer considered passive storage vesicles for excess energy, but they
are very dynamic endocrine cells that respond to a variety of stimuli (Shuldiner, Yang et
al. 2001). In the Pomc_1_; Tgl+ mice, the adipocyte's integration of both central and
peripheral stimuli results in a markedly large increase in white fat depots. Adipocytes do
however express the melanocortin receptor MC2 and in vitro studies have shown this
receptor responds to ACTH by inducing lipolysis (Oelofsen and Ramachandran 1983;
Boston and Cone 1996; Boston 1999). However, if indeed melanocortins are able to
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induce lipolysis in vivo, it appears that this ability is masked by other stimuli. One such
stimulus we believe could be that of glucocorticoids, which are elevated in Pomc_1_; Tgl+
mice (see following chapter) and are known transcription factors that can down regulate
preadipocyte factor-1 (pref-1 ), an inhibitor to the differentiation of preadipocytes to
mature adipocytes (Wolf 1999). In addition, glucocorticoids are known catabolic agents.
Their inhibition of cellular uptake of amino acids and glucose and thus inhibiting protein
synthesis results in a net decrease in metabolism (Brown 1994). Our data suggests the
exaggerated obesity is caused by a reduction in basal metabolic rate (BMR) in the Pomc_1_

; Tgl+ mice, and this BMR reduction is most likely due to the replacement of
glucocorticoids.

Although an increase in absolute food intake was observed, this

phenotype may be secondary to the metabolic defect and similar to what was observed in
the MC4-R KO mice (Ste Marie, Miura et al. 2000). Feeding studies preceding obesity
along with pair-fed studies with wild type, Pomc-1-, and Pomc_1_; Tgl+ siblings will need
to be conducted to determine if hyperphagia is secondary to a the metabolic defect.
While we believe our data indicates that the increase in white fat mass is due to a
decrease in basal metabolism, we cannot exclude that a shift in energy partitioning may
also be contributing to the obesity phenotype. Such pair-feeding studies will also help
evaluate any differences in energy partitioning that may underlie the observed obesity
phenotypes.

In humans, accumulation of intra-abdominal fat correlates with insulin resistance,
whereas subcutaneous fat deposition correlates with increased circulating leptin levels
(Havel 2001; Oberbauer, Runstadler et al. 2001; Cnop, Landchild et al. 2002). The
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excessive amount of subcutaneous fat found in the Pomc_1_; Tgl+ mice, presumably due to
the replacement of circulating corticosterone in the absence of hypothalamic POMC,
explains the very high fasting leptin levels seen in these Pomc_1_; Tg/+ mice. The Pomc_,_
mice did not have nearly the amount of subcutaneous fat as the Pomc_1_; Tg/+ mice and 2
to 3 fold lower plasma leptin levels; yet conversely, they had very large gonadal fat pads,
a subset of the mouse's intra-abdominal white fat, which in humans and mice tends to be
directly proportional with insulin resistance (Masuzaki, Paterson et al. 2001; Cnop,
Landchild et al. 2002). However, glucose-tolerance tests of Pomc_,_ mice showed only a
mild shift in their ability to clear glucose unlike the Pomc_1_; Tg/+ mice.

Paradoxically, it may be the lack of circulating corticosterone in the Pomc_,_mice causing
the disproportional accumulation of gonadal fat, and giving Pomc_,_ mice exogenous
glucocorticoids for an extended period of time and then subsequently measuring gonadal
fat could help explain this phenotype. We hypothesize that glucocorticoids play an
inhibitory role in the accumulation of intra-abdominal fat and are responsible for
directing energy storage elsewhere like subcutaneous fat and/or the liver, where
gluconeogenesis is stimulated by corticosterone. It should be noted that the Pomc_1_; Tgl+
mice had very large fatty livers. The lack of glucocorticoids in the Pomc_,_ mice could
then lead to intra-abdominal fat accumulation. Intra-abdominal fat, as compared to
subcutaneous fat, is known to have an increased lipolytic response via the stimulation of
existing adrenergic receptors (Kahn and Flier 2000). An alternative hypothesis is that the

Pomc_,_ mice, which lack the catecholamine epinephrine (Yaswen, Diehl et al. 1999),
would thus lack adrenergic induced lypolysis in gonadal fat leading to an increase storage
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in this depot. Mice lacking dopamine

~-hydroxlase

(DBH), the rate-limiting enzyme in

the production of norepinephrine (NE) and epinephrine (Epi), have an increased
metabolic rate, are slightly hyperphagic, with normal amounts of white fat (Thomas and
Palmiter 1997). The increase in metabolism seen in the DBH deficient mice may
partially explain why the Pomc_1_ mice show a higher BMR when compared with Pomc_1_;

Tgl + siblings.

A major up-regulator of leptin production is insulin. It is not surprising that mice having
the highest fasting insulin levels and largest white fat depots also have the highest leptin
levels. Both insulin and leptin inhibit feeding and increase metabolism. We previously
have shown leptin's stimulatory effects on POMC neurons (Cowley, Smart et al. 2001).
Mice lacking POMC would presumably be insensitive to leptin's anorexigenic effects
that are mediated by these POMC neurons and could explain the decrease in metabolism
seen in the Pomc_1_ and Pomc_1_; Tgl+ mice. In addition, glucocorticoids have been shown
to attenuate leptin effects on feeding and metabolism (Makimura, Mizuno et al. 2003).
The reduced metabolism in Pomc_1_; Tgl+ mice from that of Pomc_1_ mice may be due to
glucocorticoid inhibiting the leptin effects on metabolism and feeding in the Pomc_1_;

Tgl+ mice. If glucocorticoids were indeed suppressing leptin 's anabolic effects it would
be through a POMC independent pathway due to the lack of central POMC.
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5.2

Glucose tolerance and insulin resistance in Pomc_1_ and Pomc_1_; Tgl+
mice

Diabetes, although a very complex endocrine disorder, can be induced by an increase in
circulating glucocorticoid levels.

The Po m c-l- mice, void of any circulating

glucocorticoids, develop a very mild type II diabetic phenotype revealed by a mild
glucose intolerance, ad libitum hyperglycemia, intra-abdominal obesity, and (in females
only) hyperinsulinemia.

These data are supported by research from the

Hochgeschwender laboratory of the Pomc_1_ mice on the 129 genetic background
(Hochgeschwender, Costa et al. 2003). Evidence from the Palmiter laboratory suggests a
tonic inhibitory role of NE and Epi on insulin secretion that is counteracted when glucose
levels rise (Ste Marie and Palmiter 2003). It has been proposed that catecholamines
inhibit both pancreatic 13-cells directly and indirectly via inhibiting the stimulatory
parasympathetic 13-cell input.

The loss of 13 -cell inhibition could explain the

hyperinsulinemic phenotype in the Pomc_1_ females that lack epinephrine. Furthermore,
insulin release can be mediated by central POMC. Such inhibition was demonstrated by
stereotaxic administration of the melanocortin receptor agonist MTII into the PVH
resulting in a suppression of insulin release (Fan, Dinulescu et al. 2000). This insulin
inhibition can be blocked with a non-specific a-adrenergic receptor anatagonist
suggesting that this central POMC regulation of insulin release is through sympathetic
input to the pancreas. The fact that the Pomc_1_ mice endocrine abnormalities depicting
type II diabetes develop in the absence of glucocorticoids suggests that glucocorticoids
are not essential for the occurrence of type II diabetes. However, we know from
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adrenalectomy studies that glucocorticoids play a role in the development of insulin
resistance and thus glucocorticoids most likely expedite the development of this disease
(Makimura, Mizuno et al. 2003). Furthermore, glucocorticoids are known mediators of
metabolism and energy storage, and we hypothesize that the presence of glucocorticoids
in the Pomc_1_; Tgl+ mice accentuates both the obesity and progression of type II diabetes
by decreasing the BMR. Interestingly, hyperglycemia is present in fasted Po me+!-; Tgl+
and Pomc_1_; Tgl+ males but not females while glucose intolerance is much more
pronounced in female Pomc_1_; Tgl+ mice. The sexual dimorphisms in these mutant mice
are most likely a result of sex steroids that have known opposing interactions on energy
homeostasis (Machinal, Dieudonne et al. 1999; Anderson, McTernan et al. 2001; Dos
Santos, Dieudonne et al. 2002).

5.3

Conclusions

In conclusion, we have demonstrated that central POMC is essential for normal energy
balance and that the obesity phenotype in the Pomc null mice could not be rescued by
genetically restoring pituitary POMC peptides. In fact, replacement of pituitary POMC
augmented the obesity phenotype by a further suppression of basal metabolic rate.
Restoration of pituitary ACTH and circulating glucocorticoids in the Pomc null
background also resulted in more profound peripheral insulin resistance and glucose
intolerance, the prime characteristics of type II diabetes mellitus. Both male and female

Pomc_1_; Tgl+ mice had a three to four fold increase in circulating leptin levels
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corresponding to their very pronounced obesity, further identifying hypothalamic POMC
neurons as a critical substrate for the development and expression of leptin resistance.
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CHAPTERV

TRANSGENIC REPLACEMENT OF PITUITARY POMC
ON THE POMC NULL BACKGROUND UNCOVERS A
MODULATORY ROLE FOR CENTRAL POMC NEURONS
IN REGULATION OF THE HYPOTHALAMICPITUITARY-ADRENAL AXIS
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1.

ABSTRACT

Mice homozygous for a proopiomelanocortin null allele (Pomc-t-) are devoid of all
POMC peptides throughout development.

Consequently, they have atrophic

adrenal glands and undetectable corticosterone levels under basal or stressed
conditions. More than half of the Pomc_,_ offspring carried by heterozygous dams
are stillborn or die within the first hours after birth. A selective transgenic rescue of
pituitary POMC expression in the null background (Pomc_ 1_; Tg/+) fully restored
adrenal development and circulating corticosterone and prevented the
characteristic partial perinatal lethality. However, adult male Pomc_1_; Tg/+ mice
exhibited

adrenal

hypertrophy

and

elevated

basal

(evels

of both

adrenocorticotrophic hormone (ACTH) and corticosterone (B) compared to their
wild-type siblings. These mice responded to restraint stress with attenuated ACTH,
but accentuated corticosterone release compared to controllittermates. In contrast,
female Pomc_1_; Tgl+ mice had normal basal and restraint-stress induced
corticosterone levels compared to control littermates.

Corticotropin-releasing

hormone (CRH) synthesis and release from hypophyseotropic neurons in the
paraventricular nucleus (PVN) of the hypothalamus are modulated by
glucocorticoid feedback mechanisms. Therefore predictably, in the absence of
circulating corticosterone, male Pomc_,_ mice had very high CRH mRNA and
immunoreactive peptide content in PVN neurons. CRH mRNA levels in the PVH of

Pomc_1_; Tgl+ mice were significantly reduced compared to Pomc_,_ mice, but
remained inappropriately higher than control Po me+I+ mice in the context of their

144

elevated circulating corticosterone. Together these data indicate that the increased
HPA axis activity of Pomc_1_; Tgl+ mice is driven pnimarily from the central nervous
system and therefore suggest an important modulatory role for central POMC
peptides in the set-point for hypothalamic CRH expression.
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2.

INTRODUCTION

The hypothalamic pituitary adrenal (HPA) axis is the biological core component utilized
in response to external or internal stressors (Vale, Spiess et al. 1981 ). The PVN acts as a
central nodal point for integrating stress levels and then releasing corticotropin-releasing
hormone (CRH) from a subset of PVN parvicellular neurons onto the anterior pituitary
gland. CRH stimulates anterior lobe POMC expressing corticotrophs that then produce
and secrete adrenocorticotrophic hormone (ACTH). ACTH released into the peripheral
circulation stimulates production and release of corticosterone from the outer cortical
layer ofthe adrenal gland [reviewed in (Brown 1994)].

A disruption in the HP A axis has profound effects on the ability of an organism to
respond to stressful stimuli. One example of HPA axis disruption is the mutant strain of
mice deficient in CRH (Crh _,} Because of their glucocorticoid deficiency, homozygous
pups exhibit defective surfactant production and lung maturation that leads to perinatal
death (Muglia, Jacobson et al. 1995; Muglia, Bae et al. 1999).

However, no

developmental defects were noted in the hypothalamus, pituitary, or adrenal glands and
replacement of glucocorticoids reverses the lung dysplasia and lethality in the Crh_,_pups.
POMC was still expressed and ACTH content was at normal levels in the pituitary glands
of these mutant mice, but the male adrenal glands and to a lesser extent the female
adrenal glands exhibited a markedly atrophic zona fasciculata (ZF) (Muglia, Jacobson et
al. 1995). The atrophic cortex in the Crh_,_ mice is much like that seen in the Pomc·ladrenals although the latter also have smaller medullary cores (Smart and Low 2003).

146

The CrH 1- mice have an impaired hormonal stress response however their behavioral
stress response is normal (Venihaki and Majzoub 2002). One might predict similar
phenotypes in the Pomc_1_ mouse which lack circulating glucocorticoids.

In addition to the production of corticosterone, the adrenal gland also secretes steroid
hormones aldosterone and androgens from the cortex and epinephrine from the medullary
core. In humans, cortisol, the corticosterone equivalent, is required for life. However,
Pomc_1_ mice lacking corticosterone are viable yet only about half of the Pomc_1_ offspring

survive suggesting a perinatal role for adrenal steroids that could not be rescued with
glucocorticoid replacement. We tested whether the transgenic replacement (Tg/+ ) of
pituitary POMC in the Pomc_1_ background was sufficient to rescue the HP A deficiencies
or whether hypothalamic POMC was required for normal HP A function.

3.

METHODS

Transgene construction and description. The construction and descritption ofpHa!Ex2*
Tg transgene (a pituitary only exprsessing POMC transgene) is detailed in the methods of

chapter 4.

Care and use of animals. A colony of Po me mutant mice was established as described

previously (Smart and Low, 2003). Pituitary Pomc-Tg mice were generated by nuclear
microinjection of the linearized, oligonucleotide marked pHalEx2* Tg into B6D2 F 2
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hybrid embryos using standard techniques as described in Chapter IV. The pHalEx2* Tg
allele was backcrossed to the C57BL/6 genetic background for two generations and
subsequently crossed onto the Pomc_1_ genetic background by an additional two
generations of heterozygous matings. Therefore the hybrid genetic background of mutant
mice used in these experiments was approximately 80% C57BL/6, 10% DBA/2, and 10%
129. Genotyping of offspring was done by PCR and described in the Methods of chapter
IV. All animals for these studies were maintained under controlled temperature and
photoperiod conditions (14 h of light, 10 h of dark; lights on, 0500 h) with food and water
provided ad libitum except for overnight fasting studies. All surgical procedures and
other experimental studies were approved by the Institutional Animal Care and Use
Committee and followed the guidelines established by the Public Health Service.

Collection of plasma, brains and pituitaries for mRNA in situ hybridization and
dissection of adrenal glands. Animals were individually housed for two days (allowing
for cage habituation) before they were sacrificed between 0700 and 1000 during the light
cycle. Mice were quickly removed from their cages and killed by decapitation in an
adjacent room within 30 sec to obtain blood for measurement of basal, non-stressed
hormone levels. Trunk blood was collected into tubes containing 1OmM EDTA and the
plasma immediately separated by centrifugation (12,000 rpm x 5 min), split into two
tubes and frozen on dry ice for later analyses. Brains and pituitaries were immediately
removed following decapitation. Brains were frozen in -78.5°C isopentane and stored at
-80°C for later sectioning. Pituitaries were submersed in a cryomold containing OCT
and frozen on dry ice. For restraint stress studies, mice were individually constrained
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inside a 50 ml conical polypropylene tube for 20 minutes, and then killed by decapitation
for trunk blood and tissue collection as described above. Adrenal glands of mice
sacrificed at 6 to 8 months of age were completely dissected away from renal white fat
and weighed wet as a pair.

Histology and immunohistochemistry. Histological analyses were performed on tissue
fixed in 4% paraformaldehyde, and 50-!-tm sections of brain or agarose embedded
pituitaries were collected with a vibratome. Free floating sections were incubated with
2% normal goat serum followed by incubation with a polyclonal rabbit anti-CRH primary
antibody (1 :4000, Peninsula, San Carlos CA) in KPBS buffer with 0.3% TritonX-1 00 at
4 oc for 48 hr. The sections were then rinsed three times in KPBS and secondary
biotinylated goat-antirabbit IgG was applied for 2 hours followed by an avidin-biotin
horseradish peroxidase complex (Vectastain Elite ABC Kit; Vector Laboratories,
Burlingame, California, USA) for 60 minutes.

The reaction was revealed by the

chromagen diaminobenzidine (DAB) containing 0.1% hydrogen peroxidase yielding a
brown precipitate.

In situ hybridization. We used mRNA in-situ hybridization in Fl progeny, utilizing the
inserted 23 bp oligo from the pHa/ Ex2 * transgene as a probe, to confirm that the
transgene was expressed in a nonnal pattern in the pituitary but not the hypothalamus
(data not shown).

After crossing the trans gene onto the POMC null background

additional in situ hybridization studies were performed with a single stranded RNA
probe. After linearization with Ncol, sense and antisense 35 S-labeled cRNA probes were
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generated using T3 and T7 polymerase from a mouse Pomc partial exon3 clone (mPomc
Ex3 ribo ). The probe is 700bp in length and is contained in the coding region of the
Pomc gene that was subcloned into pGEM-7. The antisense probe recognizes both wild

type and pHal Ex2* transgenic POMC mRNA and the POMC sense probe was used as a
control.

The POMC probes were separated from unincorporated nucleotides over

NICK™ columns [ Sephadex™ G-50 DNA Grade (Amersham Parmacia Biotech,
Piscataway, NJ)] and stored in 1ml aliquots (5-10 million cpm/ml) of hybridization buffer
(66% Formamide; 260mM NaCl; 1.318X Denhardt's solution; 13.16 mM Tris pH 8.0;
13.15% Dextran Sulfate). Slides with 16 !lm coronal sections from cryostat sectioning
were hybridized at 55°C-60°C for 24h. After hybridization, slides were washed four
times with 4XSCC, RNase digested (30 min), rinsed again in a series of SSC &
dithiothriol (DTT), dehydrated in a series of EtOH and vacuum dried and then placed on
8"Xl0" card for film exposure. CRH sense and antisense probes were made identical to
that of the POMC probes using a 578 bp Psti/Psti DNA fragment that is contained in
exon 2 of the Crh gene (gift ofDr. Audrey Seasholtz). CRH mRNA in situ hybridization
was performed identically and in parallel to the POMC mRNA in situ hybridizations.
Slides were always exposed with

eC]-microscale slides to assure that the exposure time
4

was in the linear range of the film or cassette (in situ procedure described in (Lechan, Wu
et al. 1986; Fremeau, Autelitano et al. 1989) ). Slides containing coronal brain sections
were exposed overnight to a phosphor-imaging cassette. Slides containing pituitary
sections were exposed to one-sided emulsion film (Biomax MR, Kodak) overnight. Film
was then scanned at a resolution and density of 1200 pixels. Scanned images were
analyzed using IP-Lab Gel and NIH image by quantifying a selected area that remained
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constant from section to section and easily contained nuclei of interest. Background
hybridization was quantified from a section not containing any visible hybridization
using the same area size and was then used for subtracting background hybridization
from analyzed sections. mRNA in the ArcN was analyzed on the three most robust
sections from 4 mice per genotype. Total pituitary POMC mRNA was analyzed from the
three most robust pituitary sections from 3 to 4 mice per genotype. CRH mRNA in the
PVN was analyzed on the three most robust sections from 4 mice per genotype.

Hormone assays. Hormone levels were measured in EDTA-plasma using a double

antibody ACTH IRMA kit (Nichol's Diagnostic Institute) and a single antibody
corticosterone RIA kit (ICN). Assays were carried out according to the manufacturers'
instructions with the exception that plasma samples from Pomc_1_ mice were doubled in
volume to increase the sensitivity of the kits by two-fold in an attempt to measure
hormonal concentrations expected to be below the standard curve. After this adjustment,
samples from Pomc_1_ mice were still below the minimum detection level of the kits.

Statistics. Data were analyzed by 2-way ANOVA with genotype and sex as independent

variables using Stat View Power PC version for Macintosh (version 5.0.1; SAS Institute
Inc., Cary, North Carolina, USA) except where otherwise stated. Post hoc comparisons
between groups were performed by Fisher's (PLSD), and P values < 0.05 were
considered significant.
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4.

RESULTS

4.1

Perinatal lethality was absent and adrenal gland size was restored in
Pomc·1·; Tgl+ pups

Matings of compound heterozygous/hemizygous (Pomc +!-; Tg/+ ) breeder pairs produced
the expected Mendelian frequency of offspring with the exception of Pomc·l- pups.
Significantly decreased numbers of the latter genotype compared to the 25% expected
frequency has previously been reported (Yaswen, Diehl et al. 1999; Smart and Low
2003). There was a striking absence of perinatal lethality in the Pomc_1_; Tgl + pups
compared to Pomc·l- pups (Figure 1). Adrenal glands were removed from 6-8 month old
male and female mice and wet weights of adrenal pairs were recorded (Figure 2). A
marked sexual dimorphism was apparent in the Pomc+1+, Pomc+1+;Tgl +, Pomc+1-, and
1

Pomc+-;Tg/ + groups of mice with the female glands approximately twice as large as their

male counterparts. Pomc_ 1_ mice of both sexes had atrophic adrenal glands of similar low
weight. Pituitary POMC replacement in the Pomc_ 1_; Tg/+ mice resulted in enlarged
adrenal glands in both sexes. This hypertrophy as a percentage of wild type controls was
more dramatic in males than females, reflecting the fact that wild type female adrenal
glands are normally larger then their male counterparts.
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Figure 1
Offspring numbers along with the predicted and actual percentages of pups for
each genotype from the first 73 pups born to the following breeder pairs:
homozygous Pomc·1·; +/+males X heterozygous Pomc+1-; Tg/+ females.
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Figure 1

Breeder Pair:

(-/-}X (+/-}/(Tg/+}

Offspring:

{+/-}/(Tg/+} {-/-}/{+/+}

(+/-}/(+/+}

{-/-}/{Tg/+}

Number

23

26

2

22

Predicted (%)

25

25

25

25

Actual(%)

31

36

3

30

Figure 2
Adrenal gland weights of male and female Pomc+l+, Pomc+1-, Pomc_1_ mice with
and without the pHal Ex2* transgene. Adrenal glands were weighed as a pair at
nine months of age (n=S-16). Data are reported as the mean

±

SEM. There were

significant main effects of genotype for male (Fs,6s= 42.5, p < 0.0001) and female
(Fs,s9= 32.0, p < 0.0001) mice.
** p<O.Ol; *** p<O.OOl compared to (Pomc+1+; +/+),Fisher's PLSD.
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4.2

mRNA levels for Po me mRNA in hypothalami and pituitary glands

We performed mRNA in situ hybridizations on cryostat sectioned pituitaries and
hypothalami to further confirm that the pHalEx2 * transgene selectively rescued POMC
expression in the pituitary gland. It was possible to directly compare the levels of mRNA
transcribed from the pHalEx2* transgene and the endogenous Pomc alleles because the
mouse Pomc exon 3 riboprobe hybridizes equally with the two mRNA species, which
differ only in exon 2 sequences. The pHal Ex2* transgene successfully rescued POMC
mRNA expression in both the anterior and intermediate lobes of the pituitary gland but
not the arcuate nucleus of the hypothalamus (Figure 3). Qualitatively, the distribution of

Pomc mRNA throughout the anterior lobes of Pomc_1_; Tgl+ mice was comparable to wild
type mice and to the expression patterns of previously reported trans gene constructions
containing analogous Pomc promoter regions (Hammer, Fairchild-Huntress et al. 1990;
Rubinstein, Mortrud et al. 1993; Young, Otero et al. 1998; Low, Rubinstein et al. 2001).
Quantitation of total Po me mRNA hybridization signal in both pituitary lobes revealed no
gross differences among any of the genotypes with the exception of a complete absence
of specific signal in the Pomc_1_ mice (Table 1). Keeping in mind that small differences
may not be detected in the mRNA in situ hybridization assay, these data strongly suggest
that expression from the pHal Ex2* transgene and endogenous Pomc gene must be
balanced by the same regulatory mechanisms to account for the absence of an additive or
gain-of-function effect on Pomc mRNA levels in the compound Pomc+1+; Tgl + mice and,
conversely, normal Pomc mRNA levels in the compound Pomc_1_; Tgl+ mice.
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Figure 3
POMC mRNA in-situ hybridization in 30

[!ill

cryostat coronal sections of

Pomc+1+; Pomc+1-; and Pomc·l- male mice showing normal POMC mRNA
expression in Pomc+l+ pituitary and hypothalamus (A,D); no expression in Pomc·lmice in either pituitary or hypothalami (B,E); and rescued pituitary POMC in

Pomc·'-;Tgl+ mice but still no expression in the hypothalamus (C,F).
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Figure 3

Pituitary
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Pomc -1-

Pomc -1-; Tg/+

Table 1

Basal POMC and CRH mRNA Levels
Genotype

(POMCmRNA)

Po me+!+; +I+
Pomc +!+; Tgl+
Po me+I-; +I+
Po me+I-; Tgl+
Pomc·1-; +I+
Pomc·1-; Tgl+

Pituitary

PVN

(POMCmRNA)

(CRHmRNA)

ArcN

81359 :t 10167
51500 :t 3993
59887 :t 8575
87886 :t 8043
109 :t 14.7
62108 :t 5277

1050 :t27
1346 :t 477
894 :t 162
951 :t 92
22.7 :t 2.0 a
20.6 :t 3.8

ll

:l

646 :t 18
657 :t 77
972 :t 146
906 ± 77
4238 :t 416
1263 ±350

a

"p < 0.0001 compared to (Pomc+l+; +/+), Fishet·'s PLSD.

Quantification of mRNA in situ hybridization for male mice hypothalamic and pituitary
POMC along with CRH mRNA levels in the PVN. Data are reported as the mean±
SEM.
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4.3

Basal HPA activity: ACTH and corticosterone hormone levels

Male and female mice' basal non-stressed hormone levels were measured from EDTAplasma of all six genotypes. Both male and female Pomc_1_ mice had undetectable
circulating levels of ACTH (as previously reported) while Pomc_1_; Tgl+ mice had
elevated basal ACTH levels compared to control Pomc+l+ mice (Figure 4A,B). The
significantly elevated basal ACTH levels in the male Pomc_1_; Tg/+ mice were paralleled
by a similar four-fold elevation in basal plasma B levels (Figure 4C). However, in
female Pomc_1_; Tgl + mice there was only a trend towards higher basal ACTH levels and
basal plasma corticosterone levels were the same as wild type controls (Figure 4D).

4.4

Restraint stress: ACTH and corticosterone hormone levels

Mice of all genotypes except Pomc_1_ responded briskly with elevated ACTH and
corticosterone levels in response to an acute 20 min restraint stress compared to their
corresponding basal, non-stressed levels. However, the magnitude of the ACTH stress
response was blunted in both male and female Pomc_1_; Tgl+ mice compared to wild type
mice and the other responding groups (Figure 5A,B). Corresponding measurements of
corticosterone revealed significantly greater elevations in male Pomc_1_; Tg/+ mice
compared to the stress response of other genotypes, while the female Pomc_1_; Tgl+ mice
had comparable elevations with the other genotypes of females (Figure 5C,D).
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Figure 4

Basal HP A activity in male and female mice of all six genotypes. Mice were
killed between 08:00 and 09:00 AM during there most inactive time after being
individually housed for 3 days prior to being sacrificed. (A,D) The pHal Ex2*
transgene restored circulating ACTH and B in the Pomc·l- mice. (A,C) However,
basal ACTH and B levels were significantly higher in male Pomc·1-; Tg/+ mice
then their wild type siblings (B) with only a higher trend in just ACTH levels in
female Pomc·1-; Tg/+ mice (n=3-8). Data are reported as the mean

±

SEM. Main

effects for genotype on basal plasma ACTH and corticosterone in males (F 5,25 =
5.6, p < 0.0014), (F5,2 5 = 8.6, p < 0.0001) and females (F5,27 = 2.8, p < 0.0386),
(F 5,27

=

2.1, p < 0.1022), respectively.

* p<

compared to (Pomc+1+; +/+),Fisher's PLSD.
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0.01;

** p<

0.001;

***

p< 0.0001
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Figure 5

HPA activity in male and female mice following 20 minutes of restraint stress.
Mice were killed after a 20-minute restraint stress conducted during the light
cycle. (A, C) ACTH levels were significantly lower while B levels were
significantly higher in male Pomc_1_; Tgl+ mice as compared with their wild type
siblings. (B,D) Female Pomc_1_; Tg/+ mice showed a blunted ACTH response to
the 20 minute stress while there were no differences in circulating B levels in the
female Pomc_1_; Tgl+ mice (n=2 to 10). Data are reported as the mean± SEM.
Main effects for genotype on stressed ACTH and corticosterone levels in males
(Fs,JJ = 9.0, p < 0.0001), ( Fs,31 = 4.0, p < 0.0063), and females (Fs,3s = 16.1, p <

0.0001), (F 5,38 = 14.6, p < 0.0001), respectively.

* p< 0.01; ** p< 0.001; *** p<

0.0001 compared to (Po me+!+; +I+), Fisher's PLSD.
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4.5

CRH mRNA levels in the PVN were elevated in Pomc -!- mice and not
fully suppressed in Pomc -!-,. Tgl+ mice

Negative feedback from the periphery onto the CNS is essential for regulation of the
HPA axis [reviewed in (De Kloet, Vreugdenhil et al. 1998)]. Predictably therefore,

Pomc_1_ mice lacking glucocorticoid feedback had markedly elevated steady-state CRH
mRNA levels in the hypothalamic PVN (Figure 6). However, male Pomc·1-; Tgl+ mice
with elevated plasma corticosterone had CRH mRNA levels that were two fold higher
than wild type levels (Table 1) contrary to expectations that CRH expression would be
suppressed by the glucocorticoids (Jingami, Matsukura et al. 1985).

Although not

statistically significant with the sample size used, heterozygous Pomc+l- mice had
hypothalamic CRH mRNA levels that were intermediate to that of wild type and Pomc_1_;

Tgl + mice suggesting a mild gene dosage effect (Table I).

Due to the stimulatory effects of glucocorticoids on CRH in the central nucleus of the
amygdala (CeA) as opposed to the inhibitory effects of glucocortiocids on CRH in the
PVN, we did observe mRNA levels in brain sections corresponding to the increase or
decrease in plasma glucocorticoid levels that reflected this phenomenom. Thus, CRH
expression in the CeA displayed a pattern opposite to that of CRH expression in the PVN
of corresponding brain sections. CRH mRNA levels were normal in the CeA of Po me+!+
mice although relatively higher then that seen in the PVN of Pomc+l+ mice (Figure 6A),
CRH mRNA levels were suppressed in the CeA of Pomc·l- mice lacking glucocorticoids
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(Figure 6B), and although not quantified CRH mRNA in the CeA appears restored to
normal levels in the CeA of Pomc_1_; Tg/+ mice (Figure 6C).

Immunocytochemical analysis of CRH in the PVN paralleled the results of CRH mRNA
in situ hybridization. As expected without colchicine pretreatment to inhibit axonal
transport of peptides, there was almost no immunoreactive CRH detected in cell bodies of
wild type Pomc+l+ mice, but positive neuronal processes were present (Figure 6D). In
contrast, both CRH-immunoreactive soma and processes were abundant and strongly
labeled in the PVN of Pomc_1_ mice (Figure 6E). Although not quantitative, there
appeared to be more cell-body staining of CRH neurons in the Pomc_1_; Tg/+ mice
compared to control, although clearly less than in the Pomc_1_ mice (Figure 6F).

We next tested whether a selective absence of B-endorphin, accompanied by normal
levels of the melanocortin peptides encoded by POMC, would recapitulate the observed
alteration of CRH expression in the PVN of Pomc_1_; Tg/+ mice lacking all central POMC
peptides.

Quantitative in situ hybridization for CRH was performed in C57BL/6

congenic male wild type and B-endorphin-deficient mice (Rubinstein, Mogil et al. 1996).
These mutant mice have previously been demonstrated to have normal adrenal gland size
and normal ACTH and corticosterone levels. Steady-state levels of CRH mRNA were
also identical between the wild type [429 ± 36 units (mean ± SEM, n
endorphin-deficient [444 ± 19 units (n = 5)] animals.
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=

6)] and B-

Figure 6
CRH mRNA in-situ hybridization and immunocytochemistry for CRH peptide in
30 ~--tm cryostat coronal sections of Pomc+1+; Pomc+!-; and Pomc_1_ male mice
s_h owing up regulated CRH peptide in Pomc_1_ mice. (A,C) Hypothalamic sections
showing CRH mRNA expression in the PVN and amygdale. (D,F) ICC of
hypothalami shows very robust CRH staining without any colchicines treatments.
PVN=paraventricular Nucleus; A=amygdale; 3V=third ventricle
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Figure 6
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5.

DISCUSSION

It has long been hypothesized that POMC peptides play a critical role in the development

and maturation of the adrenal gland, but whether these peptides were hypothalamic or
pituitary derived was unknown (Estivariz, Iturriza et al. 1982; Estivariz, Carino et al.
1988; Estivariz, Morano et al. 1988; Bicknell, Lomthaisong et al. 2001 ). Mice deficient
in all POMC peptides have atrophic, ACTH non-responsive adrenals (Yaswen, Diehl et
al. 1999; Smart and Low 2003). The fact that replacing pituitary POMC onto the null
background rescued adrenal size and the ability to secrete corticosterone established that
pituitary POMC was sufficient for adrenal development and maturation. The Pomc_1_;
Tgl+ mice adrenal glands were significantly larger then wild type siblings, yet this

finding is not surprising, given that these mice had elevated basal corticosterone levels. It
has long been known that humans with hypercortisolemia and rodents with chronic
ACTH stimulation develop hyperplasic adrenal glands (Kovacs, Horvath et al. 1977;
Carey, Vanna et al. 1984; Gertz, Contreras et al. 1987). Additional studies will be
needed to determine if the Pomc_1_; Tgl+ mice adrenal glands increase in size is due to
hyperplasia or hypertrophy.

Unlike the CRH1- mice, replacement of glucocorticoids via the mother 's drinking water
was unable to rescue the perinatal lethality in Pomc_1_ pups born to heterozygous mothers
(Muglia, Jacobson et al. 1995; Smart and Low 2003). Pomc_1_ pups that carry the pHal
Ex2* transgene, born also to heterozygous mothers, do not exhibit this perinatal lethality,

as demonstrated by nonnal Mendelian offspring numbers of Pomc_1_; Tgl + pups. These
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data, in combination with data from various catecholamine-deficient mice, have led us to
hypothesize that the perinatal lethality in Pomc_1_ pups is due to the lack of nonglucocorticoid adrenal hormones (Kobayashi, Morita et al. 1995; Thomas, Matsumoto et
al. 1995; Zhou, Quaife et al. 1995). The most likely adrenal candidate is epinephrine,
which is undetectable in the Pomc_1_ mice (Yaswen, Diehl et al. 1999).

When

catecholamine-deficient mice were given isoproterenol, a 13-adrenergic receptor (13-AR)
agonist, via their mother's drinking water, the number of catecholamine-deficient pups
surviving birth regained Mendelian proportions (Portbury, Chandra et al. 2003). During
birth, pups moving through the birth canal experience various degrees of hypoxia that can
lead to bradycardia. The current belief is that catecholamines, which increase during
birth, protect the fetal heart during episodes of hypoxia that commonly occurs during
labor (Slotkin and Seidler 1988; Portbury, Chandra et al. 2003). We hypothesize that the
perinatal lethality that was seen in the Pomc_1_ pups is due to the lack of epinephrine in
these mice (Figure 1).

Although replacing pituitary POMC rescued some of the phenotypes in the Pomc_1_ mice,
analyses of the stress hormones under basal and acute stress conditions revealed an
altered HP A axis when compared to wild type mice. Basal levels of ACTH and
corticostrone (B) were elevated in male Pomc_1_; Tgl + mice despite normal pituitary
POMC mRNA. However, studies with Crh_1_ mice have shown that changes in pituitary
POMC mRNA levels are not necessarily mirrored by plasma ACTH concentrations but
that plasma ACTH levels depend more on CRH stimulation of ACTH release from
corticotrophs then from an increase of POMC mRNA levels (Jacobson, Akana et al.
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1989; Muglia, Jacobson et al. 2000). Thus, the elevated basal CRH mRNA levels in the

Pomc·1·; Tgl+ mice may stimulate a greater release of ACTH from corticotrophs rather
then an increase in POMC mRNA. An increase in CRH stimulated ACTH release would
explain the observed increase in basal plasma ACTH despite no gross differences in
pituitary POMC mRNA.

The fact that we saw high levels of CRH mRNA in the face of elevated B suggests that
corticosterone's ability to inhibit CRH mRNA levels in the brain has been disrupted
and/or circumvented in the Pomc·1·; Tgl+ mice. Evidence from the Dallman laboratory
indicates that corticosterone does not directly inhibit CRH levels in the PVN, and in fact
when B was given icv it stimulated CRH mRNA levels in the PVN (Dallman, Akana et
al. 2003). As to how B inhibits CRH in the PVN remains unknown, but our data
identifies central POMC as a component ofB's inhibitory effects on hypothalamic CRH
levels. A direct projection of POMC neurons onto hypothalamic CRH neurons has
recently been established and the effects of melanocortin peptide agonists on
hypothalamic CRH expression as been stimulatory (Lu, Barsh et al. 2003).
Pharmacological studies of

~-receptor

agonists given centrally have had mixed results

(Buckingham 1986; Buckingham and Cooper 1986; Buckingham and Cooper 1986;
Tsagarakis, Rees et al. 1990; Hellbach, Gartner et al. 1998). MC4-receptors have been
localized on CRH neurons along with autoradiographic evidence for the presence of 1--lreceptors in the hypothalamic PVN, and thus CRH regulation by POMC neurons is most
likely a complex integration of expression, trafficking, and release of both melanocortins
and (3-endorphin that may have opposing effects (Lu, Barsh et al. 2003).
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An alternative hypothesis is that the loss of central POMC has removed an indirect input
onto CRH neurons rather then a direct input. Immunohistochemical analysis revealed aMSH immunoreactivity in the dorsal raphe, a predominantly serotonergic nucleus
(O'Donohue, Miller et al. 1979; Khachaturian, Lewis et al. 1984; Leger, Bonnet et al.
1994). In addition, CRH neurons also send projections to Raphe nuclei in the midbrain
stimulating these serotonergic neurons. Furthermore, serotonergic neurons that innervate
neuroendocrine control regions in both the hypothalamic paraventricular nucleus (Petrov,
Krukoff et al. 1994) and arcuate nucleus inhibit feeding (Heisler, Cowley et al. 2003).
This CRH serotonergic circuitry may explain the absence of hyperphagia in the Pomc·lmice (described in chapter IV) due to their excessive CRH levels in the PVN.
Serotonergic neurons in the dorsal Raphe nucleus also send projections back onto the
hypothalamic PVN, and activation of the serotonergic receptor 5-HT2A lead to CRH
release and increased plasma ACTH levels (Van de Kar, Javed et al. 2001). Inhibition of
these serotonergic neurons by POMC peptides would remove the serotonergic stimulation
of CRH in the PVN, and providing an indirect regulation of CRH by POMC via the
dorsal Raphe nucleus.

Although our data reveals a role of central POMC in the regulation of hypothalamic
CRH, we cannot exclude other potential peripheral signals that may be altering
hypothalamic CRH. For instance, the gut peptides like neuromedin U (NMU) and
ghrelin injected into the PVN alter feeding, and in vitro experiments with hypothalamic
explants revealed CRH stimulated secretion by NMU and ghrelin (Wren, Small et al.
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2002; Wren, Small et al. 2002). Additional studies would be intriguing and are needed in
understanding of such peripheral signals that may also affect the hypothalamic circuitry
in our mouse models.

In conclusion, the present study emphasizes the importance of both hypothalamic and
pituitary POMC in a normal functioning HP A axis. Our observations provide direct
evidence that the lack central POMC disrupts the normal corticosterone-dependent
inhibition of hypothalamic CRH. Furthermore, pituitary POMC plays an essential role in
the survivability of pups during the perinatal period.
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SUMMARY AND CONCLUSIONS

My hypotheses were that hypothalamic POMC peptides play essential roles in regulating
energy homeostasis while pituitary POMC peptides stimulate glucocorticoid and melanin
production, and furthermore that these distinct physiological functions cannot be
compensated by POMC peptides from the other cell types.

Because the POMC

prohormone is selectively processed into multiple bioactive peptides in hypothalamic
neurons and pituitary endocrine cells in a dissimilar manner, deciphering the
physiological functions of these peptides in separate cell types was challenging. The goal
of my studies was to selectively remove POMC peptides from one group of cells while
leaving normal expression of POMC peptides in the other cells. Using murine models
that were either ubiquitously deficient in POMC peptides or were only deficient in
hypothalamic POMC, I was able to assess and compare loss of function phenotypes in the
two models. My analyses have allowed me to conclude that hypothalamic POMC is a
critical component in the regulation of energy homeostasis within the CNS that cannot be
compensated by pituitary POMC peptides. In fact, replacement of pituitary POMC
augmented the obesity phenotype by a further suppression of basal metabolic rate.
Furthermore, mice expressing pituitary POMC and lacking hypothalamic POMC had
more pronounced characteristics of type II diabetes mellitus then their ubiquitous POMC
deficient siblings. Collectively, these data emphasize the interactions and communication
that can occur between the CNS and periphery, and it's these interactions that need to be
assessed when evaluating mouse models that have tissue specific deletions of specific
genes.
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The weight phenotypes in our mouse models revealed that normal energy homeostasis
occurs only when central and peripheral POMC systems are intact. The same is true
regarding the need for both hypothalamic and pituitary POMC for a normal stress
response. My data reinforce previous studies showing that the loss of pituitary POMC
results in an abnormal stress response, however this thesis provides novel evidence that
not only pituitary POMC but also hypothalamic POMC is needed for a normal stress
response. Our analyses have provided new insight into the hypothalamic regulation of
CRH. In mice lacking central POMC, we have shown CRH is not down regulated in the
presence of elevated circulating corticosterone as would be predicted. The disruption of
normal hypothalamic circuitry has led to an abnormal hypothalamic-pituitary-adrenal
axis even after pituitary POMC has been transgenically replaced. These data identified
central POMC as a regulating component of the classical stress-axis. This thesis
emphasizes the importance of both hypothalamic and pituitary POMC in a normal
functioning HP A axis, however further genetic, pharmacological, and anatomical
experiments are required to unveil the mechanism and circuitry underlying hypothalamic
POMC regulation of CRH.

We don't know why hypothalamic POMC regulates CRH expression. One hypothesis is
that during a mammal's fed state hypothalamic POMC expression increases not only to
decrease food intake but also to directly or indirectly down regulate hypothalamic CRH.
CRH down regulation in the PVN by POMC during the fed state may communicate that
the mouse is not stressed due to lack of food as opposed to a mouse that would be
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extremely stressed in a fasted condition. However, future experiments including i.c.v.
injections of POMC agonists in the null rescued animals are necessary to test the above
hypothesis.

The generation of mice lacking only central POMC has not only further defined the
biological roles of POMC, but has also definitively identified which POMC cells carry
out these biological functions. We accomplished this by comparing wild type mice,
ubiquitous deleted POMC mice, and CNS only deleted POMC mice under identical
experimental paradigms.

The data obtained have led us to conclude that the

anorexogenic effects of POMC are a function of hypothalamic POMC neurons. Our data
have thus challenged previous claims that a-MSH may be acting as a peripheral
anorexigenic agent (Yaswen, Diehl et al. 1999). Although our data do not conclusively
exclude peripheral a-MSH as a lipolytic peptide, the fact that mice lacking only central
POMC peptides have a greater white fat mass than mice lacking both central and
peripheral POMC peptides argues against a-MSH having a peripheral lipolytic role. An
alternative explanation is that the presence of glucocorticoids in the pituitary rescued
POMC null (Pomc· 1·; Tgl+ ) mice masks any putative lipolytic effects of pituitary a-MSH.
Although we uncovered no evidence indicating that a-MSH induced lypolysis, peripheral
a-MSH may have altered the partitioning of energy stores due to the differences in white
fat accumulation in mice with or without peripheral a-MSH. To test such a hypothesis
one would need to selectively remove a-MSH without removing the other POMC
peptides and circulating glucocorticoids.
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While our data suggest that a-MSH is not a lipolytic agent, we knew from previous
studies that a-MSH is a potent agonist for the MC1-R. In vitro stimulation of this
receptor by a-MSH leads to an increase in adenylyl cyclase and the downstream signal
transduction pathway initiating the production of eumelanin pigment. Because the in
vitro antagonism of MC 1-R blocks adenylyl cyclase production, and the in vivo

antagonism of MCI-R on melanocytes results in the conversion of eumelanin to
phaeomelanin production, we were surprised to find that mice lacking the endogenous
agonist a-MSH had a uniform black coat color on the agouti-less C57Bl/6 genetic
background. Our data have led us to conclude that in the C57BL/6 genetic background
the endogenous MC1-R has sufficient basal activity to stimulate eumelanin production in
the absence of a-MSH. Alternatively, one cannot rule out the existence of an additional
unidentified endogenous agonist. A detailed histological and biochemical analyses of
both skin and hair from our mouse models is pending. These data will help to identify
any subtle difference in the skin and/or hair that was not apparent by visual observation.

The homeostatic roles of the POMC peptides described within this thesis emphasize the
importance of appropriate POMC gene regulation within an organism. Using cosmid
clones from genomic mouse DNA containing the Pomc gene, a variety of DNA reporter
constructs were designed to express EGFP under the transcriptional control of the POMC
promoter. These reporter constructs containing deleted distal sequences have identified
DNA flanking regions containing cis elements that regulate neuronal versus pituitary
expression of the Pomc gene. These constructs have helped us successfully map the
essential neuronal cis elements for POMC expression to a region -10.5 to -9.0 kb from
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the POMC promoter. Sequencing of this region will be essential for identifying known
or novel transcriptional elements regulating POMC gene expression. Furthermore, these
DNA sequences will be used to determine what trans elements bind to these regions, and
thus further our understanding ofPOMC gene transcription. These putative cis and trans
elements would be key molecular targets for understanding physiological events such as
leptin desensitization, age-related obesity and age-related decreases in basal metabolic
rates. Removal of these elements from a mouse could possibly recapitulate some or all of
the phenotypes seen in our POMC mutants, and thus highlight pharmacological targets
for therapeutic treatment of endocrine disorders like obesity and diabetes.

A large portion of this thesis centers on the role of POMC in relation to energy
homeostasis. We validate our studies along with realizing the necessity to further our
understanding beyond the data presented within this thesis by emphasizing the potential
clinical impact of such research. The FDA sponsored task force, established to identify
ways to assist and educate the general population in making wise dietary choices that
benefit long-term health, pointed out that dietary factors and sedentary lifestyles
contribute substantially to the burden of preventable illnesses and premature deaths in the
United States.

This task force revealed that dietary factors are associated with four of

the ten leading causes of death: coronary heart disease, some types of cancer, stroke, and
type II diabetes (NCHS 1997). The Centers for Disease Control and Prevention have
projected using current trends that the number of obese United States citizens will jump
from 20 percent of adults today to 80 percent by the year 2040, and the population of
normal weight individuals will drop from 42 percent today to 5 percent in the year 2040
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(Ford, Mokdad et al. 2003; Mokdad, Ford et al. 2003). Understanding how the body
maintains a balance of energy intake, expenditure, and storage is crucial for developing
preventative and/or therapeutic measures to alleviate elevate these public health
problems. My data generated from mouse mutants not only show the integral role of
central POMC in maintaining energy balance but also reveal the independent, although
not exclusive, potent effects of glucocorticoids on energy balance and partitioning in the
absence of central POMC. Ultimately, the complexity of the POMC system has allowed
and will continue to allow scientists to propose multiple options for therapeutic
treatments and prevention for obesity and its associated diseases.
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